51
|
Yamada T. [Medical ethics in genomic medicine]. Rinsho Ketsueki 2023; 64:1235-1242. [PMID: 37899205 DOI: 10.11406/rinketsu.64.1235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/31/2023]
Abstract
Recently, utilization of genetic data has become routine in medicine. It is important to consider the use of genetic information in different situations based on the principles of medical ethics. Furthermore, it is necessary to understand the features of genetic information and to adhere to various guidelines in research and clinical practices. In genomic medicine, which will become the mainstream of medicine using comprehensive genetic information, it will be crucial to fully comprehend the suitable handling of secondary results, and to prioritize benefits to the patients. Moreover, developing a system that incorporates appropriate legislation to ensure nondiscrimination of patients on the basis of their genetic information and to provide a forum for ethical issues that will arise in the future is essential.
Collapse
|
52
|
Morimoto-Ishikawa D, Hanaoka K, Watanabe S, Yamada T, Yamakawa Y, Minagawa S, Takenouchi S, Ohtani A, Mizuta T, Kaida H, Ishii K. Evaluation of the performance of a high-resolution time-of-flight PET system dedicated to the head and breast according to NEMA NU 2-2012 standard. EJNMMI Phys 2022; 9:88. [PMID: 36525103 PMCID: PMC9758266 DOI: 10.1186/s40658-022-00518-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Accepted: 12/06/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND This study evaluated the physical performance of a positron emission tomography (PET) system dedicated to the head and breast according to the National Electrical Manufacturers Association (NEMA) NU2-2012 standard. METHODS The spatial resolution, sensitivity, scatter fraction, count rate characteristics, corrections for count losses and randoms, and image quality of the system were determined. All measurements were performed according to the NEMA NU2-2012 acquisition protocols, but image quality was assessed using a brain-sized phantom. Furthermore, scans of the three-dimensional (3D) Hoffmann brain phantom and mini-Derenzo phantom were acquired to allow visual evaluation of the imaging performance for small structures. RESULTS The tangential, radial, and axial full width at half maximum (FWHM) at a 10-mm offset in half the axial field of view were measured as 2.3, 2.5, and 2.9 mm, respectively. The average system sensitivity at the center of the field of view and at a 10-cm radial offset was 7.18 and 8.65 cps/kBq, respectively. The peak noise-equivalent counting rate was 35.2 kcps at 4.8 kBq/ml. The corresponding scatter fraction at the peak noise-equivalent counting rate was 46.8%. The peak true rate and scatter fraction at 8.6 kBq/ml were 127.8 kcps and 54.3%, respectively. The percent contrast value for a 10-mm sphere was approximately 50%. On the 3D Hoffman brain phantom image, the structures of the thin layers composing the phantom were visualized on the sagittal and coronal images. On the mini-Derenzo phantom, each of the 1.6-mm rods was clearly visualized. CONCLUSION Taken together, these results indicate that the head- and breast-dedicated PET system has high resolution and is well suited for clinical PET imaging.
Collapse
Affiliation(s)
- Daisuke Morimoto-Ishikawa
- grid.413111.70000 0004 0466 7515Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University Hospital, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511 Japan
| | - Kohei Hanaoka
- grid.413111.70000 0004 0466 7515Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University Hospital, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511 Japan
| | - Shota Watanabe
- grid.413111.70000 0004 0466 7515Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University Hospital, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511 Japan
| | - Takahiro Yamada
- grid.413111.70000 0004 0466 7515Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University Hospital, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511 Japan
| | - Yoshiyuki Yamakawa
- grid.274249.e0000 0004 0571 0853Medical Systems Division, Shimadzu Corporation, Kyoto, Japan
| | - Suzuka Minagawa
- grid.274249.e0000 0004 0571 0853Medical Systems Division, Shimadzu Corporation, Kyoto, Japan
| | - Shiho Takenouchi
- grid.274249.e0000 0004 0571 0853Medical Systems Division, Shimadzu Corporation, Kyoto, Japan
| | - Atsushi Ohtani
- grid.274249.e0000 0004 0571 0853Medical Systems Division, Shimadzu Corporation, Kyoto, Japan
| | - Tetsuro Mizuta
- grid.274249.e0000 0004 0571 0853Medical Systems Division, Shimadzu Corporation, Kyoto, Japan
| | - Hayato Kaida
- grid.413111.70000 0004 0466 7515Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University Hospital, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511 Japan ,grid.258622.90000 0004 1936 9967Department of Radiology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - Kazunari Ishii
- grid.413111.70000 0004 0466 7515Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University Hospital, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511 Japan ,grid.258622.90000 0004 1936 9967Department of Radiology, Kindai University Faculty of Medicine, Osakasayama, Japan
| |
Collapse
|
53
|
Takakura N, Yamada T, Tanaka T, Yokouchi M, Takayama M, Schlaeger JM, Yajima H. Acupuncture targeting the minor salivary glands for dry mouth: a case report. Acupunct Med 2022:9645284221131340. [PMID: 36510788 DOI: 10.1177/09645284221131340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Nobuari Takakura
- Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan
| | - Takahiro Yamada
- Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan
| | - Tomohiro Tanaka
- Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan
| | - Marina Yokouchi
- Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan
| | - Miho Takayama
- Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan
| | - Judith M Schlaeger
- Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan.,Department of Human Development Nursing Science, College of Nursing, University of Illinois Chicago, Chicago, IL, USA
| | - Hiroyoshi Yajima
- Department of Acupuncture and Moxibustion, Tokyo Ariake University of Medical and Health Sciences, Tokyo, Japan
| |
Collapse
|
54
|
Kameya Y, Yamada T. Titanium oxide nanoparticle coating of PMMA open flow channels for spontaneous water transport. Colloids Surf A Physicochem Eng Asp 2022. [DOI: 10.1016/j.colsurfa.2022.130265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
55
|
Pan X, Mizukami H, Hara Y, Yamada T, Yamazaki K, Kudoh K, Takeuchi Y, Sasaki T, Kushibiki H, Igawa A, Hakamada K. Diabetes mellitus impacts on expression of DNA mismatch repair protein PMS2 and tumor microenvironment in pancreatic ductal adenocarcinoma. J Diabetes Investig 2022; 14:132-144. [PMID: 36453157 PMCID: PMC9807152 DOI: 10.1111/jdi.13929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 09/10/2022] [Accepted: 10/06/2022] [Indexed: 12/03/2022] Open
Abstract
AIMS/INTRODUCTION The mismatch repair (MMR) protein recognizes DNA replication errors and plays an important role in tumorigenesis, including pancreatic ductal adenocarcinoma (PDAC). Although PMS2, a MMR protein, is degraded under oxidative stress, the effects of diabetes are still unclear. Herein, we focused on whether diabetes affected MMR protein expression in PDAC. MATERIALS AND METHODS Tissues from 61 surgically resected PDAC subjects were clinicopathologically analyzed. Immunohistochemical analysis was performed for MMR protein expression, oxidative stress, and immune cell infiltration. The change of MMR protein expression was assessed in PDAC cell lines under stimulation with 25 mM glucose and 500 μM palmitic acid. Survival curves were analyzed by the Kaplan-Meier method with the log-rank test. RESULTS Diabetes complicated with dyslipidemia significantly decreased the expression of PMS2 in PDAC tissues with an inverse correlation with the degree of oxidative stress. Palmitic acid combined with high glucose induced degradation of PMS2 protein, enhancing oxidative stress in vitro. CD8+ T-cell infiltration was associated with a short duration of type 2 diabetes (≤4 years) and a low expression of PMS2 in PDAC tissues, while CD163+ tumor-associated macrophage infiltration was increased with a long duration of diabetes (>4 years). A short duration of diabetes exhibited a better prognosis than nondiabetic subjects with PDAC (P < 0.05), while a long duration of diabetes had a worse prognosis (P < 0.05). CONCLUSIONS The different phases of diabetes have a major impact on PDAC by altering PMS2 expression and the tumor immune microenvironment, which can be targeted by an immune checkpoint inhibitor.
Collapse
Affiliation(s)
- Xuekai Pan
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan,Department of Gastroenterological SurgeryHirosaki University Graduate School of MedicineAomoriJapan
| | - Hiroki Mizukami
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan
| | - Yutaro Hara
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan,Department of Gastroenterological SurgeryHirosaki University Graduate School of MedicineAomoriJapan
| | - Takahiro Yamada
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan,Department of Gastroenterological SurgeryHirosaki University Graduate School of MedicineAomoriJapan
| | - Keisuke Yamazaki
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan,Department of Gastroenterological SurgeryHirosaki University Graduate School of MedicineAomoriJapan
| | - Kazuhiro Kudoh
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan
| | - Yuki Takeuchi
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan
| | - Takanori Sasaki
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan
| | - Hanae Kushibiki
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan
| | - Akiko Igawa
- Department of Pathology and Molecular MedicineHirosaki University Graduate School of MedicineAomoriJapan,Department of Gastroenterological SurgeryHirosaki University Graduate School of MedicineAomoriJapan
| | - Kenichi Hakamada
- Department of Gastroenterological SurgeryHirosaki University Graduate School of MedicineAomoriJapan
| |
Collapse
|
56
|
Siddika MA, Yamada T, Aoyama R, Hidaka K, Sugiyama H, Endo M, Matsumura S, Ikawa Y. Catalytic RNA Oligomers Formed by Co-Oligomerization of a Pair of Bimolecular RNase P Ribozymes. Molecules 2022; 27:molecules27238298. [PMID: 36500390 PMCID: PMC9740620 DOI: 10.3390/molecules27238298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 11/23/2022] [Accepted: 11/23/2022] [Indexed: 11/29/2022]
Abstract
Naturally occurring ribozymes with a modular architecture are promising platforms for construction of RNA nanostructures because modular redesign enables their oligomerization. The resulting RNA nanostructures can exhibit the catalytic function of the parent ribozyme in an assembly dependent manner. In this study, we designed and constructed open-form oligomers of a bimolecular form of an RNase P ribozyme. The ribozyme oligomers were analyzed biochemically and by atomic force microscopy (AFM).
Collapse
Affiliation(s)
- Mst. Ayesha Siddika
- Graduate School of Innovative Life Science, University of Toyama, Gofuku 3190, Toyama 930-8555, Japan
| | - Takahiro Yamada
- Department of Chemistry, Graduate School of Science and Engineering, University of Toyama, Gofuku 3190, Toyama 930-8555, Japan
| | - Risako Aoyama
- Department of Chemistry, Graduate School of Science and Engineering, University of Toyama, Gofuku 3190, Toyama 930-8555, Japan
| | - Kumi Hidaka
- Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto 606-8501, Japan
| | - Hiroshi Sugiyama
- Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto 606-8501, Japan
| | - Masayuki Endo
- Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto 606-8501, Japan
- Organization for Research and Development of Innovative Science and Technology, Kansai University, Osaka 564-8680, Japan
| | - Shigeyoshi Matsumura
- Graduate School of Innovative Life Science, University of Toyama, Gofuku 3190, Toyama 930-8555, Japan
- Department of Chemistry, Graduate School of Science and Engineering, University of Toyama, Gofuku 3190, Toyama 930-8555, Japan
| | - Yoshiya Ikawa
- Graduate School of Innovative Life Science, University of Toyama, Gofuku 3190, Toyama 930-8555, Japan
- Department of Chemistry, Graduate School of Science and Engineering, University of Toyama, Gofuku 3190, Toyama 930-8555, Japan
- Correspondence:
| |
Collapse
|
57
|
Chihara Y, Takeda T, Goto Y, Nakamura Y, Tsuchiya-Kawano Y, Nakao A, Onoi K, Hibino M, Fukuda M, Honda R, Yamada T, Taniguchi R, Sakamoto S, Date K, Nagashima S, Tanzawa S, Minato K, Nakatani K, Izumi M, Shimose T, Kishimoto J, Uchino J, Takayama K. A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study. Oncologist 2022; 27:903-e834. [PMID: 36181763 PMCID: PMC9632307 DOI: 10.1093/oncolo/oyac193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Accepted: 08/23/2022] [Indexed: 01/05/2023] Open
Abstract
BACKGROUND Osimertinib is one of the standard first-line treatments for advanced non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations, because it achieves significantly longer progression-free survival (PFS) than conventional first-line treatments (hazard ratio: 0.46). However, the efficacy and safety of osimertinib as a first-line treatment for patients aged ≥75 years remain unclear. METHODS This phase II study was performed to prospectively investigate the efficacy and safety of osimertinib for elderly patients with EGFR mutation-positive advanced non-small cell lung cancer. The primary endpoint was 1-year PFS rate; secondary endpoints were overall response rate (ORR), PFS, overall survival (OS), and safety. RESULTS Thirty-eight patients were included in the analysis. The 1-year PFS rate was 59.4% (95% confidence interval [CI], 46.1%-72.7%), which did not meet the primary endpoint (the threshold 1-year PFS rate of 50% predicted using data from the NEJ003 study). The most common grade 3/4 adverse events were rash/dermatitis acneiform/ALT increased/hypokalemia (2 patients, 5%). Seven patients developed pneumonitis (17.5%). There were no other cases of treatment discontinuation due to adverse events other than pneumonitis. CONCLUSION Although this study did not meet the primary endpoint, osimertinib was tolerable for elderly patients with EGFR mutation-positive advanced non-small cell lung cancer. (Japan Registry of Clinical Trials [JRCT] ID number: jRCTs071180007).
Collapse
Affiliation(s)
- Yusuke Chihara
- Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji, Japan
| | - Takayuki Takeda
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
| | - Yasuhiro Goto
- Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Japan
| | - Yoichi Nakamura
- Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Japan
| | - Yuko Tsuchiya-Kawano
- Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan
| | - Akira Nakao
- Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan
| | - Keisuke Onoi
- Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Makoto Hibino
- Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan
| | - Minoru Fukuda
- Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
| | - Ryoichi Honda
- Department of Respiratory Medicine, Asahi General Hospital, Asahi, Japan
| | - Takahiro Yamada
- Department of Pulmonary Medicine, Matsushita Memorial Hospital, Moriguchi, Japan
| | | | - Sinjiro Sakamoto
- Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan
| | - Koji Date
- Department of Pulmonary Medicine, Kyoto Chubu Medical Center, Nantan, Japan
| | - Seiji Nagashima
- Department of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Omura, Japan
| | - Shigeru Tanzawa
- Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
| | - Koichi Minato
- Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan
| | - Koichi Nakatani
- Division of Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
| | - Miiru Izumi
- Department of Respiratory Medicine, National Hospital Organization Omuta National Hospital, Omuta, Japan
| | - Takayuki Shimose
- Department of Statistics and Data Center, Clinical Research Support Center Kyushu, Fukuoka, Japan
| | - Junji Kishimoto
- Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan
| | - Junji Uchino
- Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Koichi Takayama
- Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
| |
Collapse
|
58
|
Kuyama S, Yoshioka H, Kaneda H, Kataoka Y, Miura S, Katakami N, Yamanaka Y, Tamiya A, Yamada T, Yokoyama T, Hara S, Tanaka H, Fujisaka Y, Nakamura A, Azuma K, Namba M, Hata A, Sawa K, Ishikawa H, Kurata T. 330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
59
|
Nemoto M, Tanaka A, Kaida H, Kimura Y, Nagaoka T, Yamada T, Hanaoka K, Kitajima K, Tsuchitani T, Ishii K. Automatic detection of primary and metastatic lesions on cervicothoracic region and whole-body bone using a uniform machine-learnable approach for [18F]-FDG-PET/CT image analysis. Phys Med Biol 2022; 67. [DOI: 10.1088/1361-6560/ac9173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Accepted: 09/12/2022] [Indexed: 11/12/2022]
Abstract
Abstract
We propose a method to detect primary and metastatic lesions with Fluorine−18 fluorodeoxyglucose (FDG) accumulation in the lung field, neck, mediastinum, and bony regions on the FDG-PET/CT images. To search for systemic lesions, various anatomical structures must be considered. The proposed method is addressed by using an extraction process for anatomical regions and a uniform lesion detection approach. The uniform approach does not utilize processes that reflect any region-specific anatomical aspects but has a machine-learnable framework. Therefore, it can work as a lesion detection process for a specific anatomical region if it machine-learns the specific region data. In this study, three lesion detection processes for the whole-body bone region, lung field, or neck-mediastinum region are obtained. These detection processes include lesion candidate detection and false positive (FP) candidate elimination. The lesion candidate detection is based on a voxel anomaly detection with a one-class support vector machine. The FP candidate elimination is performed using an AdaBoost classifier ensemble. The image features used by the ensemble are selected sequentially during training and are optimal for candidate classification. Three-fold cross-validation was used to detect performance with the 54 diseased FDG-PET/CT images. The mean sensitivity for detecting primary and metastatic lesions at 3 FPs per case was 0.89 with a 0.10 standard deviation (SD) in the bone region, 0.80 with a 0.10 SD in the lung field, and 0.87 with a 0.10 SD in the neck region. The average areas under the ROC curve were 0.887 with a 0.125 SD for detecting bone metastases, 0.900 with a 0.063 SD for detecting pulmonary lesions, and 0.927 with a 0.035 SD for detecting the neck-mediastinum lesions. These detection performances indicate that the proposed method could be applied clinically. These results also show that the uniform approach has high versatility for providing various lesion detection processes.
Collapse
|
60
|
Tamaki S, Nagai Y, Shutta R, Masuda D, Yamashita S, Seo M, Yamada T, Yano M, Hayashi T, Yasumura Y, Hikoso S, Sotomi Y, Sakata Y. Relation of lymphopenia to comorbidity burden and its prognostic value in patients with acute decompensated heart failure with preserved left ventricular ejection fraction: a multicentre study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Systemic inflammation resulting from comorbidities is postulated to play a central role in the pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF). Lymphopenia is a common manifestation of systemic inflammation and a prognostic factor in patients with HF. However, the association of lymphopenia with the comorbidity burden is unknown, and its prognostic value in patients with HFpEF admitted due to acute decompensated heart failure (ADHF) also remains elusive.
Purpose
We sought to clarify the relation of lymphopenia with the comorbidity burden, as well as its prognostic value and complementarity with the Get with the Guidelines-Heart Failure (GWTG-HF) risk score in ADHF patients with HFpEF.
Methods
Patients' data were extracted from the Prospective mUlticenteR obServational stUdy of patIenTs with Heart Failure with Preserved Ejection Fraction (PURSUIT-HFpEF), which is a prospective multicentre registry for patients with ADHF with a LVEF ≥50%. We analysed data of patients admitted between June 2016 and December 2020 who survived to discharge. The total lymphocyte count (per μL) and GWTG-HF risk score were obtained on admission, as previously reported. Comorbidity burden was defined as the number of comorbidities from the following: atrial fibrillation, hypertension, diabetes mellitus, coronary artery disease, chronic kidney disease, chronic obstructive pulmonary disease, anaemia, and obesity. The study endpoint was all-cause death.
Results
Over a median follow-up of 417 days, 181 of the 1013 included patients died. The proportion of patients with a total lymphocyte count in the lowest tertile was increasing with the increase in comorbidity burden (Figure 1). In the multivariate Cox analysis, a total lymphocyte count in the intermediate (hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.00–2.41, p=0.0486) and lowest tertile (HR 2.23, 95% CI 1.47–3.38, p=0.0002) was independently associated with all-cause death. There was a significant difference in the all-cause death rate among the groups stratified by total lymphocyte count tertile (Figure 2). The total lymphocyte count had a higher C-statistic value (0.627) for the prediction of all-cause death than the GWTG-HF risk score, and the C-statistic value of the GWTG-HF risk score was improved when the total lymphocyte count was added (0.613 to 0.636, p=0.0260).
Conclusions
Lymphopenia was significantly associated with comorbidity burden. Furthermore, it was a useful marker of poor prognosis in hospitalised patients with acute HFpEF and was shown to be complementary to the contemporary HF prognostic score.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Roche Diagnostics K.K.Fuji Film Toyama Chemical Co. Ltd.
Collapse
Affiliation(s)
- S Tamaki
- Rinku General Medical Center , Izumisano , Japan
| | - Y Nagai
- Rinku General Medical Center , Izumisano , Japan
| | - R Shutta
- Rinku General Medical Center , Izumisano , Japan
| | - D Masuda
- Rinku General Medical Center , Izumisano , Japan
| | - S Yamashita
- Rinku General Medical Center , Izumisano , Japan
| | - M Seo
- Osaka General Medical Center , Osaka , Japan
| | - T Yamada
- Osaka General Medical Center , Osaka , Japan
| | - M Yano
- Osaka Rosai Hospital , Sakai , Japan
| | - T Hayashi
- Osaka Police Hospital , Osaka , Japan
| | - Y Yasumura
- Amagasaki Chuo Hospital , Amagasaki , Japan
| | - S Hikoso
- Osaka University Graduate School of Medicine , Suita , Japan
| | - Y Sotomi
- Osaka University Graduate School of Medicine , Suita , Japan
| | - Y Sakata
- Osaka University Graduate School of Medicine , Suita , Japan
| |
Collapse
|
61
|
Oeun B, Hikoso S, Nakatani D, Okada K, Dohi T, Sotomi Y, Kida H, Sunaga A, Sato T, Seo M, Yano M, Hayashi T, Yamada T, Yasumura Y, Sakata Y. Clinical trajectory and outcomes of patients with heart failure with preserved ejection fraction with normal or indeterminate diastolic function. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Heart failure (HF) with preserved ejection fraction (HFpEF) is a chronic and progressive disease, but limited therapeutic strategies are currently available. Although left ventricular diastolic dysfunction (DD) is a prominent mechanism of HFpEF, a certain number of patients with HFpEF have a normal diastolic function (ND) or indeterminate diastolic function (ID). With the progressive nature of HFpEF, diastolic function may change over time. However, the change of diastolic function, its predictor and prognosis in patients with clinically established HFpEF remains unknown.
Purpose
To investigate the clinical trajectory and outcomes of patients with HFpEF with ND or ID and to identify factors associated with progression from ND or ID at discharge to DD at 1-year follow-up.
Methods
Using data from a prospective multicenter observational study of patients with HFpEF, we extracted 289 patients with HFpEF with ND or ID at discharge who had echocardiographic data at 1-year follow-up for the re-evaluation of diastolic function. Diastolic function was assessed according to the 2016 American Society of Echocardiography recommendations. Patients were classified according to the absence or presence of progression from ND or ID to DD at 1 year. The primary endpoint was a composite of all-cause death and HF rehospitalization.
Results
Median age was 81 years, and 138 (47.8%) patients were female. At 1 year, 107 (37%) patients progressed to DD. During a median follow-up of 709 days, the composite endpoint occurred in 90 (31.1%) patients. Compared to patients without progression to DD, those with progression to DD had a significantly higher cumulative incidence rate of the composite endpoint (incidence rate: 11.7/100 person-year versus 23.3/100 person-year, P<0.001). Progression to DD (adjusted HR: 2.014, 95% CI: 1.239–3.273, P=0.005) was independently associated with the composite endpoint. Age (adjusted OR: 1.046, 95% CI: 1.008–1.087, P=0.018), body mass index (BMI) (adjusted OR: 1.107, 95% CI: 1.029–1.192, P=0.006), and serum albumin (adjusted OR: 0.459, 95% CI: 0.216–0.974, P=0.042) were independently associated with progression from ND or ID to DD at 1 year.
Conclusion
More than one-third of patients with HFpEF with ND or ID progressed to DD at 1 year and had poor clinical outcomes. Age, BMI, and serum albumin were independently associated with this progression.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): This work was supported by grants from Japan Society for the Promotion of Science KAKENHI (No. JP 17K09496) and Japan Agency for Medical Research and Development (No. JP16lk1010013).
Collapse
Affiliation(s)
- B Oeun
- Osaka University Graduate School of Medicine , Suita , Japan
| | - S Hikoso
- Osaka University Graduate School of Medicine , Suita , Japan
| | - D Nakatani
- Osaka University Graduate School of Medicine , Suita , Japan
| | - K Okada
- Osaka University Graduate School of Medicine , Suita , Japan
| | - T Dohi
- Osaka University Graduate School of Medicine , Suita , Japan
| | - Y Sotomi
- Osaka University Graduate School of Medicine , Suita , Japan
| | - H Kida
- Osaka University Graduate School of Medicine , Suita , Japan
| | - A Sunaga
- Osaka University Graduate School of Medicine , Suita , Japan
| | - T Sato
- Osaka University Graduate School of Medicine , Suita , Japan
| | - M Seo
- Osaka General Medical Center, Cardiology , Osaka , Japan
| | - M Yano
- Osaka Rosai Hospital, Cardiology , Sakai , Japan
| | - T Hayashi
- Osaka Police Hospital, Cardiology , Osaka , Japan
| | - T Yamada
- Osaka General Medical Center, Cardiology , Osaka , Japan
| | - Y Yasumura
- Amagasaki Chuo Hospital, Cardiology , Amagasaki , Japan
| | - Y Sakata
- Osaka University Graduate School of Medicine , Suita , Japan
| |
Collapse
|
62
|
Sunaga A, Hikoso S, Tamaki S, Yano M, Hayashi T, Oeun B, Kida H, Sotomi Y, Dohi T, Okada K, Mizuno H, Nakatani D, Yamada T, Yasumura Y, Sakata Y. Association between prognosis and the use of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blocker in frail patients with heart failure with preserved ejection fraction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The effectiveness of angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) has not been demonstrated in patients with heart failure with preserved ejection fraction (HFpEF). We recently reported significant interaction between the use of ACE-I and/or ARB (ACE-I/ARB) and frailty on prognosis in patients with HFpEF.
Purpose
In the present study, we examined the association between ACE-I/ARB and prognosis in patients with HFpEF stratified by the presence or absence of frailty.
Methods
We examined the association between the use of ACE-I/ARB and prognosis according to the presence (Clinical Frailty Scale (CFS) ≥5) or absence (CFS ≤4) of frailty in patients with HFpEF in a post-hoc analysis of registry data. Primary endpoint was the composite of all-cause mortality and heart failure admission. Secondary endpoints were all-cause mortality and heart failure admission.
Results
Of 1059 patients, median age was 83 years and 45% were male. Kaplan-Meier analysis showed that the risk of composite endpoint (log-rank P=0.001) and all-cause death (log-rank P=0.005) in patients with ACE-I/ARB was lower in those with CFS ≥5, but similar between patients with and without ACE-I/ARB in patients with CFS ≤4 (composite endpoint: log-rank P=0.830; all-cause death: log-rank P=0.192). In a multivariable Cox proportional hazards model, use of ACE-I/ARB was significantly associated with lower risk of the composite endpoint (hazard ratio = 0.52, 95% CI: 0.33–0.83, P=0.005) and heart failure admission (hazard ratio = 0.45, 95% CI: 0.25–0.83, P=0.010) in patients with CFS ≥5, but not in patients with CFS ≤4 (composite endpoint: hazard ratio = 1.41, 95% CI: 0.99–2.02, P=0.059; heart failure admission: hazard ratio = 1.43, 95% CI: 0.94–2.18, P=0.091). The association between ACE-I or ARB and prognosis did not significantly differ by CFS (CFS ≤4: log-rank P=0.562; CFS ≥5: log-rank P=0.100, for with ACE-I vs. ARB, respectively). Adjusted HRs for CFS 1–4 were higher than 1.0, but were less than 1.0 at CFS 5.
Conclusions
In patients with HFpEF, use of ACE-I/ARB was associated with better prognosis in patients with frailty as assessed with the CFS, but not in those without frailty.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Roche
Collapse
Affiliation(s)
- A Sunaga
- Osaka University Graduate School of Medicine , Suita , Japan
| | - S Hikoso
- Osaka University Graduate School of Medicine , Suita , Japan
| | - S Tamaki
- Osaka General Medical Center, Cardiology , Osaka , Japan
| | - M Yano
- Osaka Rosai Hospital , Sakai , Japan
| | - T Hayashi
- Osaka Police Hospital , Osaka , Japan
| | - B Oeun
- Osaka University Graduate School of Medicine , Suita , Japan
| | - H Kida
- Osaka University Graduate School of Medicine , Suita , Japan
| | - Y Sotomi
- Osaka University Graduate School of Medicine , Suita , Japan
| | - T Dohi
- Osaka University Graduate School of Medicine , Suita , Japan
| | - K Okada
- Osaka University Graduate School of Medicine , Suita , Japan
| | - H Mizuno
- Osaka University Graduate School of Medicine , Suita , Japan
| | - D Nakatani
- Osaka University Graduate School of Medicine , Suita , Japan
| | - T Yamada
- Osaka General Medical Center, Cardiology , Osaka , Japan
| | - Y Yasumura
- Amagasaki Central Hospital, Cardiology , Amagasaki , Japan
| | - Y Sakata
- Osaka University Graduate School of Medicine , Suita , Japan
| |
Collapse
|
63
|
Seo M, Watanabe T, Yamada T, Yano M, Hayashi T, Yasumura Y, Hikoso S, Sotomi Y, Sakata Y. The clinical relevance of quality of life in patients with acute decompensated heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF Registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Improvement of quality of life (QOL) is one of the most important therapeutic goals for patients with heart failure with preserved ejection fraction (HFpEF). It is, therefore, clinically relevant to comprehensively identify aggravating factors among cardiac factors, non-cardiac comorbidities, and social factors. The aim of this study was to elucidate determinant factors of impaired QOL and clarify the association between QOL and prognosis in patients with HFpEF.
Methods and results
Patient data were extracted from The Prospective mUlticenteR obServational stUdy of patIenTs with Heart Failure with Preserved Ejection Fraction (PURSUIT HFpEF) study. EuroQol 5 dimensions 5-level (EQ-5D-5L) data were obtained at discharge to evaluate patients' health-related QOL. A total of 864 patients were enrolled in this study. Multivariable logistic regression analysis revealed that only non-cardiac factors such as age, female sex, frailty, malnutrition and inflammation were significantly associated with low EQ-5D-5L score, whereas cardiac factors showed no significant association after multivariable adjustment. A total of 206 patients died over a mean follow-up period of 2.0±1.2 years. Kaplan–Meier survival curve analysis demonstrated a significant increase in risk of mortality stratified by tertiles of EQ-5D-5L score (p<0.0001). Cox multivariable analysis revealed that patients with low EQ-5D-5L score had a significantly greater risk of mortality than those with high EQ-5D-5L score (adjusted hazard ratio: 2.20 (1.40–3.45), p=0.001).
Conclusion
Among patients with HFpEF, non-cardiac factors such as age, female sex, frailty, malnutrition and inflammation are significantly associated with impaired QOL. The QOL score itself also offers useful prognostic information in patients with HFpEF.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- M Seo
- Osaka General Medical Center, Cardiology , Osaka , Japan
| | - T Watanabe
- Osaka General Medical Center, Cardiology , Osaka , Japan
| | - T Yamada
- Osaka General Medical Center, Cardiology , Osaka , Japan
| | - M Yano
- Osaka Rosai Hospital, Cardiology , Osaka , Japan
| | - T Hayashi
- Osaka Police Hospital, Cardiology , Osaka , Japan
| | - Y Yasumura
- Amagasaki Central Hospital, Cardiology , Amagasaki , Japan
| | - S Hikoso
- Osaka University Graduate School of Medicine, Cardiovascular Medicine , Osaka , Japan
| | - Y Sotomi
- Osaka University Graduate School of Medicine, Cardiovascular Medicine , Osaka , Japan
| | - Y Sakata
- Osaka University Graduate School of Medicine, Cardiovascular Medicine , Osaka , Japan
| |
Collapse
|
64
|
Nakagawa Y, Sairyo M, Miyazawa K, Tamaki S, Yano M, Hayashi T, Yamada T, Yasumura Y, Hikoso S, Sotomi Y, Sakata Y. Insight into the relationship between heart rate and mortality in patients in sinus rhythm with heart failure with preserved ejection fraction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
There are several reports showing that elevated heart rate (HR) is associated with poor outcomes in patients in sinus rhythm (SR) with heart failure with preserved ejection fraction (HFpEF), although the association is weak or none in HFpEF patients with atrial fibrillation (Af). However, in previous studies, cardiac and non-cardiac factors which may be associated with elevated HR, have not been fully adjusted for.
Purpose
The purpose of this study is to explore covariates of elevated HR and to investigate the relationship between heart rate and mortality in HFpEF patients in SR.
Methods and results
Of the 1161 patients, who registered prospective multicenter, observational study of patients with HFpEF (PURSUIT-HFpEF), 726 patients in SR were examined. We performed laboratory testing and echocardiography in the compensated stage (in stable condition after treatment of acute decompensated HF). Geriatric nutritional risk index (GNRI) was calculated as nutrition index. Resting heart rate (HR) was analyzed as categorical (tertiles, T1–3). We followed the patients for median of 598 days (interquartile range 329–1028 days) to observe the outcome all-cause mortality.
The Kaplan analysis revealed that there was a significant difference between heart rate and mortality (log-rank, p=0.001). Characteristics were compared between patients in T1 (HR ≤63) and T3 (HR ≥75). There were no differences in cardiac factors between patients in T1 and T3. C-reactive protein (CRP) was significantly higher in patients in T3 than those in T1 (p=0.0004,). GNRI was significantly lower in patients in T3 than those in T1 (p=0.001). After adjustment for covariates including N-terminal pro-B type natriuretic peptide and estimated glomerular filtration rate, CRP and GNRI significantly correlated with HR (continuous variable) by multiple regression analysis (beta-coefficient = 1.52, p=0.003 and beta-coefficient = −0.14, p=0.04, respectively). Taking T1 as the reference, multivariable Cox regression analysis revealed that T3 was independently associated with mortality (hazard ratio: 2.10, 95% confidence interval: 1.33–3.32, p=0.001).
Conclusion
Although elevated HR was associated with enhanced inflammation and malnutrition, it itself was an independent predictor of death in HFpEF patients in SR.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Roche Diagnosis K.K.Fuji Film Toyama Chemical Co. Ltd.
Collapse
Affiliation(s)
- Y Nakagawa
- Kawanishi city Hospital , Kawanishi , Japan
| | - M Sairyo
- Kawanishi city Hospital , Kawanishi , Japan
| | - K Miyazawa
- Kawanishi city Hospital , Kawanishi , Japan
| | - S Tamaki
- Osaka General Medical Center , Osaka , Japan
| | - M Yano
- Osaka Rosai Hospital , Osaka , Japan
| | - T Hayashi
- Osaka Police Hospital , Osaka , Japan
| | - T Yamada
- Osaka General Medical Center , Osaka , Japan
| | - Y Yasumura
- Amagasaki Central Hospital , Amagasaki , Japan
| | - S Hikoso
- Osaka University Graduate School of Medicine , Suita , Japan
| | - Y Sotomi
- Osaka University Graduate School of Medicine , Suita , Japan
| | - Y Sakata
- Osaka University Graduate School of Medicine , Suita , Japan
| |
Collapse
|
65
|
Sakamoto D, Seo M, Yamada T, Yano M, Hayashi T, Yasumura Y, Hikoso S, Sotomi Y, Sakata Y. Prognostic impact of the serial change of a systemic inflammation-nutrition index in patients with heart failure with preserved ejection fraction: insights from pursuit-hfpef registry. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Malnutrition and inflammation are associated with poor outcomes with heart failure (HF). It has been reported that advanced lung cancer inflammation index (ALI), calculated by body mass index × serum albumin level / neutrophil to lymphocyte ratio (NLR) can be useful for the risk stratification and predicting the post-discharge prognosis of the patients with acute decompensated heart failure (ADHF). However, there is no information available on the prognostic value of the serial ALI change in ADHF patients with preserved ejection fraction (HFpEF).
Methods and results
Patients' data were extracted from The Prospective mUlticenteR obServational stUdy of patIenTs with Heart Failure with Preserved Ejection Fraction (PURSUIT HFpEF) study, which is a prospective multicenter observational registry for ADHF-HFpEF in Osaka. Laboratory data and body weight measurements were performed at the discharge and 1 year after the discharge. We analyzed 527 patients after exclusion of patients on dialysis, in-hospital death, missing follow-up data, or missing data to calculate ALI. The study patients were categorized by the serial change from baseline to 1 year after the discharge (ΔALI) as follows: low tertile: ΔALI <−6.99 (n=176), middle tertile: −6.99 ≤ ALI <8.44 (n=176), and high tertile: 8.44 ≤ ΔALI (n=175). The endpoints of the present study were all-cause death (ACD) and cardiovascular death (CVD). During a mean follow-up period of 1.5±1.0 years, 94 patients had ACD and 40 patients had CVD. The Kaplan-Meier analysis revealed that the patients with middle and low ΔALI at 1 year after heart failure hospitalization had a significantly greater risk of reaching the ACD and CVD than those with high ΔALI (ACD: 22% vs 22% vs 10%, p=0.0011, CVD: 10% vs 9% vs 3%, p=0.014). On multivariate Cox analysis, ΔALI was significantly associated with ACD independently of age, gender, serum NT-proBNP level, and baseline ALI after adjustment for NYHA functional class, serum creatinine level, serum hemoglobin level, serum CRP level, serum sodium level and LVEF.
Conclusion
This study showed that patients with the increased ALI after the discharge had improved outcome in comparison to those without the increased ALI. The serial change of ALI, a systemic inflammation-nutrition index, might be useful for stratifying ADHF patients with HFpEF at risk for the total mortality and cardiovascular mortality.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- D Sakamoto
- Osaka General Medical Center , Osaka , Japan
| | - M Seo
- Osaka General Medical Center , Osaka , Japan
| | - T Yamada
- Osaka General Medical Center , Osaka , Japan
| | - M Yano
- Osaka Rosai Hospital, Cardiology , Osaka , Japan
| | - T Hayashi
- Osaka Police Hospital, Cardiology , Osaka , Japan
| | - Y Yasumura
- Amagasaki Chuo Hospital, Cardiology , Amagasaki , Japan
| | - S Hikoso
- Osaka University Graduate School of Medicine, Cardiology , Osaka , Japan
| | - Y Sotomi
- Osaka University Graduate School of Medicine, Cardiology , Osaka , Japan
| | - Y Sakata
- Osaka University Graduate School of Medicine, Cardiology , Osaka , Japan
| |
Collapse
|
66
|
Mino Y, Naito T, Ohshiro J, Yamada T, Kawakami J. Investigation of the boxed warnings in package inserts of prescription medicines for medical professionals in Japan. Pharm Pract (Granada) 2022; 20:2733. [PMID: 36793916 PMCID: PMC9891776 DOI: 10.18549/pharmpract.2022.4.2733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Accepted: 09/12/2022] [Indexed: 12/14/2022] Open
Abstract
Objective In the Japanese Pharmacists Act, article 25-2, revised in 2013, it states that pharmacists shall provide the necessary information and guidance to the patient based on pharmaceutical knowledge and experience for ensuring the proper use of the medicine dispensed. The package insert is one of the documents to be referred to when providing the information and guidance. The boxed warnings in package inserts that include the precautions and responses are the most significant parts, however, the suitability of boxed warnings for pharmaceutical practice has not been evaluated. The aim of this study was to investigate the boxed warning descriptions in package inserts of prescription medicines for medical professionals in Japan. Methods Package inserts of prescription medicines listed in the Japanese National Health Insurance drug price list on March 1st 2015 were collected one by one by hand from the website of the Japanese Pharmaceuticals and Medical Devices Agency (https://www.pmda.go.jp/english/). Package inserts with boxed warnings were classified according to the Standard Commodity Classification Number of Japan based on the pharmacological activity of each medicine. They were also compiled according to their formulations. The boxed warnings were divided into the precautions and responses parts, and their characteristics were compared among medicines. Results The number of package inserts found on the website of the Pharmaceuticals and Medical Devices Agency was 15,828. Boxed warnings were present in 8.1% of the package inserts. A description of adverse drug reactions accounted for 74% of all precautions. Most of the precautions were observed in the warning boxes of antineoplastic agents. Blood and lymphatic system disorders were the most common precaution. Responses in the boxed warnings directed toward medical doctors, pharmacists, and other healthcare professionals accounted for 100, 77, and 8% of all package inserts with a boxed warning, respectively. Explanations for patients were the second most frequent response. Conclusions The majority of boxed warnings request therapeutic contribution by pharmacists, and the descriptions of these explanations and guidance by pharmacists to patients were found to be consistent with the Pharmacists Act.
Collapse
Affiliation(s)
- Yasuaki Mino
- Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan.
| | - Takafumi Naito
- Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan.
| | - Junya Ohshiro
- Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan.
| | - Takahiro Yamada
- Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan.
| | - Junichi Kawakami
- Department of Hospital Pharmacy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu 431-3192, Japan.
| |
Collapse
|
67
|
Sunami T, Yamada A, Kondo T, Kanai M, Nagai K, Uchida Y, Yokode M, Matsumori T, Uza N, Murakami H, Yamada T, Muto M. Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant. Pancreas 2022; 51:1258-1262. [PMID: 37078954 DOI: 10.1097/mpa.0000000000002150] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/21/2023]
Abstract
ABSTRACT Pancreatic cancer and its rare subtype, acinar cell carcinoma (PACC), frequently harbor germline and/or somatic variants in homologous recombinant genes, including BRCA2. Individuals possessing germline pathogenic BRCA2 variants are known to have a higher risk of developing various cancers, including breast, ovarian, pancreatic, and bile duct cancers (BDCs). It has been reported that tumors positive for BRCA1/2 variants are sensitive to platinum-based agents. Thus, BRCA1/2 germline testing and comprehensive genomic profiling are recommended to identify genetic susceptibility and to indicate optimal targeted therapy. Here, we report familial occurrence of PACC and BDC associated with BRCA2; both tumors responded exceptionally well to platinum-based chemotherapy. A 37-year-old man was diagnosed with unresectable PACC with a germline BRCA2 variant. He was treated with oxaliplatin-containing chemotherapy and conversion surgery, and remains alive without tumor recurrence after more than 36 months. His father also possessed the identical germline BRCA2 variant and was diagnosed with extrahepatic BDC with lymph node metastases. The tumors showed marked shrinkage upon treatment with cisplatin-containing chemotherapy. Our cases underscore the importance of comprehensive genomic profiling and genetic testing for BRCA2 to ensure optimal therapeutic options for PACC as well as to identify high-risk individuals with various cancers in the family.
Collapse
Affiliation(s)
| | | | | | - Masashi Kanai
- Department of Clinical Oncology, Kyoto University Hospital
| | - Kazuyuki Nagai
- Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery
| | - Yoichiro Uchida
- Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery
| | - Masataka Yokode
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University
| | - Tomoaki Matsumori
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University
| | - Norimitsu Uza
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University
| | - Hiromi Murakami
- Clinical Genetics Unit, Kyoto University Hospital, Kyoto, Japan
| | - Takahiro Yamada
- Clinical Genetics Unit, Kyoto University Hospital, Kyoto, Japan
| | | |
Collapse
|
68
|
Komuro J, Tokuoka Y, Seki T, Kusumoto D, Hashimoto H, Katsuki T, Nakamura T, Akiba Y, Kuoka T, Kimura M, Yamada T, Fukuda K, Funahashi A, Yuasa S. Development of non-bias phenotypic drug screening for cardiomyocyte hypertrophy by image segmentation using deep learning. Biochem Biophys Res Commun 2022; 632:181-188. [DOI: 10.1016/j.bbrc.2022.09.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 09/15/2022] [Accepted: 09/27/2022] [Indexed: 11/02/2022]
|
69
|
Mizuta T, Yamakawa Y, Minagawa S, Kobayashi T, Ohtani A, Takenouchi S, Hanaoka K, Watanabe S, Morimoto-Ishikawa D, Yamada T, Kaida H, Ishii K. Attenuation correction for phantom tests: an alternative to maximum-likelihood attenuation correction factor-based correction for clinical studies in time-of-flight PET. Ann Nucl Med 2022; 36:998-1006. [PMID: 36167889 DOI: 10.1007/s12149-022-01788-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Accepted: 09/14/2022] [Indexed: 11/25/2022]
Abstract
OBJECTIVES This study evaluates the phantom attenuation correction (PAC) method as an alternative to maximum-likelihood attenuation correction factor (ML-ACF) correction in time-of-flight (TOF) brain positron emission tomography (PET) studies. METHODS In the PAC algorithm, a template emission image [Formula: see text] and a template attenuation coefficient image [Formula: see text] are prepared as a data set based on phantom geometry. Position-aligned attenuation coefficient image [Formula: see text] is derived by aligning [Formula: see text] using parameters that match the template emission image [Formula: see text] to measured emission image [Formula: see text]. Then, attenuation coefficient image [Formula: see text] combined with a headrest image is used for scatter and attenuation correction in the image reconstruction. To evaluate the PAC algorithm as an alternative to ML-ACF, Hoffman 3D brain and cylindrical phantoms were measured to obtain the image quality indexes of contrast and uniformity. These phantoms were also wrapped with a radioactive sheet to obtain attenuation coefficient images using ML-ACF. Emission images were reconstructed with attenuation correction by PAC and ML-ACF, and the results were compared using contrast and uniformity as well as visual assessment. CT attenuation correction (CT-AC) was also applied as a reference. RESULTS The contrast obtained by ML-ACF was slightly overestimated due to its unique experimental condition for applying ML-ACF in Hoffman 3D brain phantom but the uniformity was almost equivalent among ML-ACF, CT-AC, and PAC. PAC showed reasonable result without overestimation compared to ML-ACF and CT-AC. CONCLUSIONS PAC is an attenuation correction method that can ensure the performance in phantom test, and is considered to be a reasonable alternative to clinically used ML-ACF-based attenuation correction.
Collapse
Affiliation(s)
- Tetsuro Mizuta
- Medical Systems Division, Shimadzu Corporation, 1, Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto, 604-8511, Japan.
| | - Yoshiyuki Yamakawa
- Medical Systems Division, Shimadzu Corporation, 1, Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto, 604-8511, Japan
| | - Suzuka Minagawa
- Medical Systems Division, Shimadzu Corporation, 1, Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto, 604-8511, Japan
| | | | - Atsushi Ohtani
- Medical Systems Division, Shimadzu Corporation, 1, Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto, 604-8511, Japan
| | - Shiho Takenouchi
- Medical Systems Division, Shimadzu Corporation, 1, Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto, 604-8511, Japan
| | - Kohei Hanaoka
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan
| | - Shota Watanabe
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan
| | - Daisuke Morimoto-Ishikawa
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan
| | - Takahiro Yamada
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan
| | - Hayato Kaida
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan.,Department of Radiology, Faculty of Medicine, Kindai University, Osakasayama, Japan
| | - Kazunari Ishii
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan.,Department of Radiology, Faculty of Medicine, Kindai University, Osakasayama, Japan
| |
Collapse
|
70
|
Shiotsu S, Yoshimura A, Yamada T, Morimoto K, Tsuchiya M, Yoshioka H, Hiranuma O, Chihara Y, Yamada T, Hasegawa I, Ohta T, Takeda T, Hiraoka N, Takayama K. Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. Front Oncol 2022; 12:904644. [PMID: 36158655 PMCID: PMC9504658 DOI: 10.3389/fonc.2022.904644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 08/18/2022] [Indexed: 11/13/2022] Open
Abstract
Objectives We investigated the efficacy and safety of pembrolizumab monotherapy as first-line treatment for poor Eastern Cooperative Oncology Group performance status (PS) and elderly patients with programmed cell death-ligand 1 (PD-L1)-positive advanced non-small cell lung cancer (NSCLC). We also investigated clinical prognostic factors for the efficacy of pembrolizumab monotherapy, based on patient characteristics. Materials and methods In this prospective observational study, PS-2 and elderly NSCLC patients with PD-L1 tumor proportion score (TPS) ≥1% who received first-line pembrolizumab monotherapy, from October 2019 to March 2021, at 10 institutions in Japan were enrolled. Patients judged eligible by their physicians for combined chemotherapy and PD-1/PD-L1 inhibitors as first-line treatment were excluded. Clinicopathological characteristics and adverse events were investigated for correlation with clinical outcomes. Results Forty patients were enrolled in the study. The median progression-free survival (PFS) of patients with PS 2 and those aged ≥ 75 years were 4.4 (95% confidence interval [CI]: 0.9–14.4) months and 5.3 (95% CI 2.9–9.4) months, respectively. The median overall survival (OS) of patients with PS 2 and those aged ≥ 75 years were 11.6 (95% CI: 1.4–not evaluable [NE]) months and 11.6 (95% CI 7.4–18.1) months, respectively. Immune-related adverse events (irAEs) were observed in 19 patients; 6 patients had severe irAEs of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or higher. Patients who achieved stable disease or better, had a statistically significant increase in PFS (p < 0.001) and OS (p < 0.001). In the multivariate analysis, the acquisition of disease control with pembrolizumab monotherapy was an independent prognostic factor for PFS and OS. Conclusion Pembrolizumab monotherapy was relatively effective and tolerable as a first-line treatment for patients with PD-L1-positive advanced NSCLC who had poor PS or were elderly. Our results suggest that disease control might be an independent prognostic factor for PFS and OS in this population. (UMIN000044052 https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050176)
Collapse
Affiliation(s)
- Shinsuke Shiotsu
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
| | - Akihiro Yoshimura
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Tadaaki Yamada
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
- *Correspondence: Tadaaki Yamada,
| | - Kenji Morimoto
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Michiko Tsuchiya
- Department of Respiratory Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan
| | - Hiroshige Yoshioka
- Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan
| | - Osamu Hiranuma
- Department of Respiratory Medicine, Otsu City Hospital, Shiga, Japan
| | - Yusuke Chihara
- Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, Japan
| | - Takahiro Yamada
- Department of Respiratory Medicine, Matsushita Memorial Hospital, Osaka, Japan
| | - Isao Hasegawa
- Department of Respiratory Medicine, Saiseikai Shigaken Hospital, Shiga, Japan
| | - Takahiro Ohta
- Department of Respiratory Medicine, Kyoto City Hospital, Kyoto, Japan
| | - Takayuki Takeda
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
| | - Noriya Hiraoka
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
| | - Koichi Takayama
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| |
Collapse
|
71
|
Uda S, Yamada T, Yoshimura A, Goto Y, Yoshimine K, Nakamura Y, Shiotsu S, Yokoi T, Tamiya N, Kimura H, Chihara Y, Umeda Y, Izumi M, Takeda T, Yamada T, Hibino M, Hiranuma O, Ito K, Okada A, Osugi S, Takemura Y, Ishii H, Chibana K, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res 2022; 11:1847-1857. [PMID: 36248326 PMCID: PMC9554692 DOI: 10.21037/tlcr-22-160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 07/11/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Sayaka Uda
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Tadaaki Yamada
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Akihiro Yoshimura
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Yasuhiro Goto
- Department of Respiratory Medicine, Fujita Health University School of Medicine, Aichi, Japan
| | - Kohei Yoshimine
- Department of Respiratory Medicine, Izuka Hospital, Fukuoka, Japan
| | - Yoichi Nakamura
- Division of Thoracic Oncology, Tochigi Cancer Center, Tochigi, Japan
| | - Shinsuke Shiotsu
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan
| | - Takashi Yokoi
- Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan
| | - Nobuyo Tamiya
- Department of Pulmonary Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan
| | - Hideharu Kimura
- Department of Respiratory Medicine, Kanazawa University, Ishikawa, Japan
| | - Yusuke Chihara
- Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Kyoto, Japan
| | - Yukihiro Umeda
- Third Department of Internal Medicine, Faculty of Medical Science, University of Fukui, Fukui, Japan
| | - Miiru Izumi
- Department of Respiratory Medicine, National Hospital Organization Omuta National Hospital, Fukuoka, Japan
| | - Takayuki Takeda
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan
| | - Takahiro Yamada
- Department of Pulmonary Medicine, Matsushita Memorial Hospital, Osaka, Japan
| | - Makoto Hibino
- Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, Kanagawa, Japan
| | - Osamu Hiranuma
- Department of Pulmonary Medicine, Otsu City Hospital, Shiga, Japan
| | - Kazuhiro Ito
- Department of Thoracic Surgery, Kyoto Yamashiro Medical Center, Kyoto, Japan
| | - Asuka Okada
- Department of Respiratory Medicine, Saiseikai Suita Hospital, Osaka, Japan
| | - Shuji Osugi
- Department of Respiratory Medicine, Japan Community Health Care Organization Kobe Central Hospital, Hyogo, Japan
| | - Yoshizumi Takemura
- Department of Respiratory Medicine, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan
| | - Hiroshi Ishii
- Department of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka, Japan
| | - Kenji Chibana
- Department of Respiratory Medicine, National Hospital Organization Okinawa National Hospital, Okinawa, Japan
| | - Isao Hasegawa
- Department of Respiratory Medicine, Saiseikai Shiga Hospital, Shiga, Japan
| | - Yoshie Morimoto
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Masahiro Iwasaku
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Shinsaku Tokuda
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Koichi Takayama
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| |
Collapse
|
72
|
Nisbet G, Beutier G, De Boissieu M, Yamada T, Takakura H. Fingerprinting phason strain. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322095493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
73
|
Takeuchi Y, Mizukami H, Kudoh K, Osonoi S, Sasaki T, Kushibiki H, Ogasawara S, Hara Y, Igawa A, Pan X, Yamada T, Yamazaki K, Mikami T, Daimon M, Yagihashi S, Hakamada K, Nakaji S. The diversity and abundance of gut microbiota are associated with the pain sensation threshold in the Japanese population. Neurobiol Dis 2022; 173:105839. [PMID: 35988875 DOI: 10.1016/j.nbd.2022.105839] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 08/02/2022] [Accepted: 08/13/2022] [Indexed: 10/15/2022] Open
Abstract
Small fibre neuropathy (SFN) is an initial pathology of diabetic polyneuropathy (DPN). Serum lipopolysaccharide binding protein levels are positively correlated with the pain threshold in the foot, suggesting that the abundance of gut Gram-negative bacilli, which are a source of lipopolysaccharides, may be involved in the development of DPN. Furthermore, the abundance of the gut and oral microbiota is assumed to be involved in the pathogenesis of diabetes. Nevertheless, the association between SFN and the microbiota has not been clarified. A total of 1056 individuals were recruited in the 2018 Iwaki Health Promotion Project. Pain sensation was evaluated based on the pain threshold from intraepidermal electrical stimulation (PINT). Patients with PINT scores <0.15 mA were categorized into the low-PINT group (n = 718); otherwise, they were categorized into the high-PINT group (n = 283). Furthermore, each group was divided into the subjects with or without glucose tolerance based on HbA1c levels, fasting blood glucose levels and diabetic history. Principal coordinate analysis and α- and β-diversity of the microbiota were evaluated. The correlation between clinical and microbiota data was examined. Oral microbiota diversity showed no structural differences according to PINT scores, whereas principal coordinate analysis and α- and β-diversity revealed significant structural differences in gut microbiota (p < 0.01, p < 0.05 and p < 0.05, respectively), even after the participants with glucose intolerance were excluded (p < 0.01, p < 0.05 and p < 0.05, respectively). The relative abundance of the genus Bacteroides was significantly lower in high-PINT participants compared with low-PINT participants (10 ± 6.7% vs. 11.3 ± 7.0%, p < 0.01), even after the exclusion of subjects with diabetes and impaired fasting glucose (10.0 ± 6.5% vs. 11.2 ± 6.9%, p < 0.05). In univariate linear regression analyses, PINT was significantly correlated with metabolic syndrome parameters, eGFR, uric acid level and the abundance of Bacteroides. The correlation between Bacteroides and PINT scores remained significant after adjustment for multiple factors (β = -0.07181, p < 0.05). Changes of bacterial diversity and a low abundance of gut Bacteroides were correlated with elevated PINT scores in the Japanese population. This correlation may represent a new therapeutic option for SFN.
Collapse
Affiliation(s)
- Yuki Takeuchi
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan; Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Hiroki Mizukami
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan.
| | - Kazuhiro Kudoh
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Sho Osonoi
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan; Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Takanori Sasaki
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Hanae Kushibiki
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Saori Ogasawara
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Yutaro Hara
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan; Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Akiko Igawa
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan; Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Xuekai Pan
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan; Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Takahiro Yamada
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan; Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Keisuke Yamazaki
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan; Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Tatsuya Mikami
- Innovation Center for Health Promotion, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Makoto Daimon
- Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Soroku Yagihashi
- Department of Pathology and Molecular Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Kenichi Hakamada
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| | - Shigeyuki Nakaji
- Department of Social Medicine, Hirosaki University Graduate School of Medicine, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan
| |
Collapse
|
74
|
Abbott R, Abe H, Acernese F, Ackley K, Adhikari N, Adhikari R, Adkins V, Adya V, Affeldt C, Agarwal D, Agathos M, Agatsuma K, Aggarwal N, Aguiar O, Aiello L, Ain A, Ajith P, Akutsu T, Albanesi S, Alfaidi R, Allocca A, Altin P, Amato A, Anand C, Anand S, Ananyeva A, Anderson S, Anderson W, Ando M, Andrade T, Andres N, Andrés-Carcasona M, Andrić T, Angelova S, Ansoldi S, Antelis J, Antier S, Apostolatos T, Appavuravther E, Appert S, Apple S, Arai K, Araya A, Araya M, Areeda J, Arène M, Aritomi N, Arnaud N, Arogeti M, Aronson S, Arun K, Asada H, Asali Y, Ashton G, Aso Y, Assiduo M, Melo SADS, Aston S, Astone P, Aubin F, AultONeal K, Austin C, Babak S, Badaracco F, Bader M, Badger C, Bae S, Bae Y, Baer A, Bagnasco S, Bai Y, Baird J, Bajpai R, Baka T, Ball M, Ballardin G, Ballmer S, Balsamo A, Baltus G, Banagiri S, Banerjee B, Bankar D, Barayoga J, Barbieri C, Barish B, Barker D, Barneo P, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton M, Bartos I, Basak S, Bassiri R, Basti A, Bawaj M, Bayley J, Mills J, Milotti E, Minenkov Y, Mio N, Mir L, Miravet-Tenés M, Mishkin A, Mishra C, Mishra T, Mistry T, Bazzan M, Mitra S, Mitrofanov V, Mitselmakher G, Mittleman R, Miyakawa O, Miyo K, Miyoki S, Mo G, Modafferi L, Moguel E, Becher B, Mogushi K, Mohapatra S, Mohite S, Molina I, Molina-Ruiz M, Mondin M, Montani M, Moore C, Moragues J, Moraru D, Bécsy B, Morawski F, More A, Moreno C, Moreno G, Mori Y, Morisaki S, Morisue N, Moriwaki Y, Mours B, Mow-Lowry C, Bedakihale V, Mozzon S, Muciaccia F, Mukherjee A, Mukherjee D, Mukherjee S, Mukherjee S, Mukherjee S, Mukund N, Mullavey A, Munch J, Beirnaert F, Muñiz E, Murray P, Musenich R, Muusse S, Nadji S, Nagano K, Nagar A, Nakamura K, Nakano H, Nakano M, Bejger M, Nakayama Y, Napolano V, Nardecchia I, Narikawa T, Narola H, Naticchioni L, Nayak B, Nayak R, Neil B, Neilson J, Belahcene I, Nelson A, Nelson T, Nery M, Neubauer P, Neunzert A, Ng K, Ng S, Nguyen C, Nguyen P, Nguyen T, Benedetto V, Quynh LN, Ni J, Ni WT, Nichols S, Nishimoto T, Nishizawa A, Nissanke S, Nitoglia E, Nocera F, Norman M, Beniwal D, North C, Nozaki S, Nurbek G, Nuttall L, Obayashi Y, Oberling J, O’Brien B, O’Dell J, Oelker E, Ogaki W, Benjamin M, Oganesyan G, Oh J, Oh K, Oh S, Ohashi M, Ohashi T, Ohkawa M, Ohme F, Ohta H, Okada M, Bennett T, Okutani Y, Olivetto C, Oohara K, Oram R, O’Reilly B, Ormiston R, Ormsby N, O’Shaughnessy R, O’Shea E, Oshino S, Bentley J, Ossokine S, Osthelder C, Otabe S, Ottaway D, Overmier H, Pace A, Pagano G, Pagano R, Page M, Pagliaroli G, BenYaala M, Pai A, Pai S, Pal S, Palamos J, Palashov O, Palomba C, Pan H, Pan KC, Panda P, Pang P, Bera S, Pankow C, Pannarale F, Pant B, Panther F, Paoletti F, Paoli A, Paolone A, Pappas G, Parisi A, Park H, Berbel M, Park J, Parker W, Pascucci D, Pasqualetti A, Passaquieti R, Passuello D, Patel M, Pathak M, Patricelli B, Patron A, Bergamin F, Paul S, Payne E, Pedraza M, Pedurand R, Pegoraro M, Pele A, Arellano FP, Penano S, Penn S, Perego A, Berger B, Pereira A, Pereira T, Perez C, Périgois C, Perkins C, Perreca A, Perriès S, Pesios D, Petermann J, Petterson D, Bernuzzi S, Pfeiffer H, Pham H, Pham K, Phukon K, Phurailatpam H, Piccinni O, Pichot M, Piendibene M, Piergiovanni F, Pierini L, Bersanetti D, Pierro V, Pillant G, Pillas M, Pilo F, Pinard L, Pineda-Bosque C, Pinto I, Pinto M, Piotrzkowski B, Piotrzkowski K, Bertolini A, Pirello M, Pitkin M, Placidi A, Placidi E, Planas M, Plastino W, Pluchar C, Poggiani R, Polini E, Pong D, Betzwieser J, Ponrathnam S, Porter E, Poulton R, Poverman A, Powell J, Pracchia M, Pradier T, Prajapati A, Prasai K, Prasanna R, Beveridge D, Pratten G, Principe M, Prodi G, Prokhorov L, Prosposito P, Prudenzi L, Puecher A, Punturo M, Puosi F, Puppo P, Bhandare R, Pürrer M, Qi H, Quartey N, Quetschke V, Quinonez P, Quitzow-James R, Raab F, Raaijmakers G, Radkins H, Radulesco N, Bhandari A, Raffai P, Rail S, Raja S, Rajan C, Ramirez K, Ramirez T, Ramos-Buades A, Rana J, Rapagnani P, Ray A, Bhardwaj U, Raymond V, Raza N, Razzano M, Read J, Rees L, Regimbau T, Rei L, Reid S, Reid S, Reitze D, Bhatt R, Relton P, Renzini A, Rettegno P, Revenu B, Reza A, Rezac M, Ricci F, Richards D, Richardson J, Richardson L, Bhattacharjee D, Riemenschneider G, Riles K, Rinaldi S, Rink K, Robertson N, Robie R, Robinet F, Rocchi A, Rodriguez S, Rolland L, Bhaumik S, Rollins J, Romanelli M, Romano R, Romel C, Romero A, Romero-Shaw I, Romie J, Ronchini S, Rosa L, Rose C, Bianchi A, Rosińska D, Ross M, Rowan S, Rowlinson S, Roy S, Roy S, Rozza D, Ruggi P, Ruiz-Rocha K, Ryan K, Bilenko I, Sachdev S, Sadecki T, Sadiq J, Saha S, Saito Y, Sakai K, Sakellariadou M, Sakon S, Salafia O, Salces-Carcoba F, Billingsley G, Salconi L, Saleem M, Salemi F, Samajdar A, Sanchez E, Sanchez J, Sanchez L, Sanchis-Gual N, Sanders J, Sanuy A, Bini S, Saravanan T, Sarin N, Sassolas B, Satari H, Sauter O, Savage R, Savant V, Sawada T, Sawant H, Sayah S, Birney R, Schaetzl D, Scheel M, Scheuer J, Schiworski M, Schmidt P, Schmidt S, Schnabel R, Schneewind M, Schofield R, Schönbeck A, Birnholtz O, Schulte B, Schutz B, Schwartz E, Scott J, Scott S, Seglar-Arroyo M, Sekiguchi Y, Sellers D, Sengupta A, Sentenac D, Biscans S, Seo E, Sequino V, Sergeev A, Setyawati Y, Shaffer T, Shahriar M, Shaikh M, Shams B, Shao L, Sharma A, Bischi M, Sharma P, Shawhan P, Shcheblanov N, Sheela A, Shikano Y, Shikauchi M, Shimizu H, Shimode K, Shinkai H, Shishido T, Biscoveanu S, Shoda A, Shoemaker D, Shoemaker D, ShyamSundar S, Sieniawska M, Sigg D, Silenzi L, Singer L, Singh D, Singh M, Bisht A, Singh N, Singha A, Sintes A, Sipala V, Skliris V, Slagmolen B, Slaven-Blair T, Smetana J, Smith J, Smith L, Biswas B, Smith R, Soldateschi J, Somala S, Somiya K, Song I, Soni K, Soni S, Sordini V, Sorrentino F, Sorrentino N, Bitossi M, Soulard R, Souradeep T, Sowell E, Spagnuolo V, Spencer A, Spera M, Spinicelli P, Srivastava A, Srivastava V, Staats K, Bizouard MA, Stachie C, Stachurski F, Steer D, Steinlechner J, Steinlechner S, Stergioulas N, Stops D, Stover M, Strain K, Strang L, Blackburn J, Stratta G, Strong M, Strunk A, Sturani R, Stuver A, Suchenek M, Sudhagar S, Sudhir V, Sugimoto R, Suh H, Blair C, Sullivan A, Summerscales T, Sun L, Sunil S, Sur A, Suresh J, Sutton P, Suzuki T, Suzuki T, Suzuki T, Blair D, Swinkels B, Szczepańczyk M, Szewczyk P, Tacca M, Tagoshi H, Tait S, Takahashi H, Takahashi R, Takano S, Takeda H, Blair R, Takeda M, Talbot C, Talbot C, Tanaka K, Tanaka T, Tanaka T, Tanasijczuk A, Tanioka S, Tanner D, Tao D, Bobba F, Tao L, Tapia R, Martín ETS, Taranto C, Taruya A, Tasson J, Tenorio R, Terhune J, Terkowski L, Thirugnanasambandam M, Bode N, Thomas M, Thomas P, Thompson E, Thompson J, Thondapu S, Thorne K, Thrane E, Tiwari S, Tiwari S, Tiwari V, Boër M, Toivonen A, Tolley A, Tomaru T, Tomura T, Tonelli M, Tornasi Z, Torres-Forné A, Torrie C, e Melo IT, Töyrä D, Bogaert G, Trapananti A, Travasso F, Traylor G, Trevor M, Tringali M, Tripathee A, Troiano L, Trovato A, Trozzo L, Trudeau R, Boldrini M, Tsai D, Tsang K, Tsang T, Tsao JS, Tse M, Tso R, Tsuchida S, Tsukada L, Tsuna D, Tsutsui T, Bolingbroke G, Turbang K, Turconi M, Tuyenbayev D, Ubhi A, Uchikata N, Uchiyama T, Udall R, Ueda A, Uehara T, Ueno K, Bonavena L, Ueshima G, Unnikrishnan C, Urban A, Ushiba T, Utina A, Vajente G, Vajpeyi A, Valdes G, Valentini M, Valsan V, Bondu F, van Bakel N, van Beuzekom M, van Dael M, van den Brand J, Van Den Broeck C, Vander-Hyde D, van Haevermaet H, van Heijningen J, van Putten M, van Remortel N, Bonilla E, Vardaro M, Vargas A, Varma V, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch P, Venneberg J, Venugopalan G, Bonnand R, Verkindt D, Verma P, Verma Y, Vermeulen S, Veske D, Vetrano F, Viceré A, Vidyant S, Viets A, Vijaykumar A, Booker P, Villa-Ortega V, Vinet JY, Virtuoso A, Vitale S, Vocca H, von Reis E, von Wrangel J, Vorvick C, Vyatchanin S, Wade L, Boom B, Wade M, Wagner K, Walet R, Walker M, Wallace G, Wallace L, Wang J, Wang J, Wang W, Ward R, Bork R, Warner J, Was M, Washimi T, Washington N, Watchi J, Weaver B, Weaving C, Webster S, Weinert M, Weinstein A, Boschi V, Weiss R, Weller C, Weller R, Wellmann F, Wen L, Weßels P, Wette K, Whelan J, White D, Whiting B, Bose N, Whittle C, Wilken D, Williams D, Williams M, Williamson A, Willis J, Willke B, Wilson D, Wipf C, Wlodarczyk T, Bose S, Woan G, Woehler J, Wofford J, Wong D, Wong I, Wright M, Wu C, Wu D, Wu H, Wysocki D, Bossilkov V, Xiao L, Yamada T, Yamamoto H, Yamamoto K, Yamamoto T, Yamashita K, Yamazaki R, Yang F, Yang K, Yang L, Boudart V, Yang YC, Yang Y, Yang Y, Yap M, Yeeles D, Yeh SW, Yelikar A, Ying M, Yokoyama J, Yokozawa T, Bouffanais Y, Yoo J, Yoshioka T, Yu H, Yu H, Yuzurihara H, Zadrożny A, Zanolin M, Zeidler S, Zelenova T, Zendri JP, Bozzi A, Zevin M, Zhan M, Zhang H, Zhang J, Zhang L, Zhang R, Zhang T, Zhang Y, Zhao C, Zhao G, Bradaschia C, Zhao Y, Zhao Y, Zhou R, Zhou Z, Zhu X, Zhu ZH, Zucker M, Zweizig J, Brady P, Bramley A, Branch A, Branchesi M, Brau J, Breschi M, Briant T, Briggs J, Brillet A, Brinkmann M, Brockill P, Brooks A, Brooks J, Brown D, Brunett S, Bruno G, Bruntz R, Bryant J, Bucci F, Bulik T, Bulten H, Buonanno A, Burtnyk K, Buscicchio R, Buskulic D, Buy C, Byer R, Davies GC, Cabras G, Cabrita R, Cadonati L, Caesar M, Cagnoli G, Cahillane C, Bustillo JC, Callaghan J, Callister T, Calloni E, Cameron J, Camp J, Canepa M, Canevarolo S, Cannavacciuolo M, Cannon K, Cao H, Cao Z, Capocasa E, Capote E, Carapella G, Carbognani F, Carlassara M, Carlin J, Carney M, Carpinelli M, Carrillo G, Carullo G, Carver T, Diaz JC, Casentini C, Castaldi G, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Cella G, Cerdá-Durán P, Cesarini E, Chaibi W, Subrahmanya SC, Champion E, Chan CH, Chan C, Chan C, Chan K, Chan M, Chandra K, Chang I, Chanial P, Chao S, Chapman-Bird C, Charlton P, Chase E, Chassande-Mottin E, Chatterjee C, Chatterjee D, Chatterjee D, Chaturvedi M, Chaty S, Chen C, Chen D, Chen H, Chen J, Chen K, Chen X, Chen YB, Chen YR, Chen Z, Cheng H, Cheong C, Cheung H, Chia H, Chiadini F, Chiang CY, Chiarini G, Chierici R, Chincarini A, Chiofalo M, Chiummo A, Choudhary R, Choudhary S, Christensen N, Chu Q, Chu YK, Chua S, Chung K, Ciani G, Ciecielag P, Cieślar M, Cifaldi M, Ciobanu A, Ciolfi R, Cipriano F, Clara F, Clark J, Clearwater P, Clesse S, Cleva F, Coccia E, Codazzo E, Cohadon PF, Cohen D, Colleoni M, Collette C, Colombo A, Colpi M, Compton C, Constancio M, Conti L, Cooper S, Corban P, Corbitt T, Cordero-Carrión I, Corezzi S, Corley K, Cornish N, Corre D, Corsi A, Cortese S, Costa C, Cotesta R, Cottingham R, Coughlin M, Coulon JP, Countryman S, Cousins B, Couvares P, Coward D, Cowart M, Coyne D, Coyne R, Creighton J, Creighton T, Criswell A, Croquette M, Crowder S, Cudell J, Cullen T, Cumming A, Cummings R, Cunningham L, Cuoco E, Curyło M, Dabadie P, Canton TD, Dall’Osso S, Dálya G, Dana A, D’Angelo B, Danilishin S, D’Antonio S, Danzmann K, Darsow-Fromm C, Dasgupta A, Datrier L, Datta S, Datta S, Dattilo V, Dave I, Davier M, Davis D, Davis M, Daw E, Dean R, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Favero V, De Lillo F, De Lillo N, Dell’Aquila D, Del Pozzo W, DeMarchi L, De Matteis F, D’Emilio V, Demos N, Dent T, Depasse A, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, De Simone R, Dhurandhar S, Díaz M, Didio N, Dietrich T, Di Fiore L, Di Fronzo C, Di Giorgio C, Di Giovanni F, Di Giovanni M, Di Girolamo T, Di Lieto A, Di Michele A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Divakarla A, Dmitriev A, Doctor Z, Donahue L, D’Onofrio L, Donovan F, Dooley K, Doravari S, Drago M, Driggers J, Drori Y, Ducoin JG, Dupej P, Dupletsa U, Durante O, D’Urso D, Duverne PA, Dwyer S, Eassa C, Easter P, Ebersold M, Eckhardt T, Eddolls G, Edelman B, Edo T, Edy O, Effler A, Eguchi S, Eichholz J, Eikenberry S, Eisenmann M, Eisenstein R, Ejlli A, Engelby E, Enomoto Y, Errico L, Essick R, Estellés H, Estevez D, Etienne Z, Etzel T, Evans M, Evans T, Evstafyeva T, Ewing B, Fabrizi F, Faedi F, Fafone V, Fair H, Fairhurst S, Fan P, Farah A, Farinon S, Farr B, Farr W, Fauchon-Jones E, Favaro G, Favata M, Fays M, Fazio M, Feicht J, Fejer M, Fenyvesi E, Ferguson D, Fernandez-Galiana A, Ferrante I, Ferreira T, Fidecaro F, Figura P, Fiori A, Fiori I, Fishbach M, Fisher R, Fittipaldi R, Fiumara V, Flaminio R, Floden E, Fong H, Font J, Fornal B, Forsyth P, Franke A, Frasca S, Frasconi F, Freed J, Frei Z, Freise A, Freitas O, Frey R, Fritschel P, Frolov V, Fronzé G, Fujii Y, Fujikawa Y, Fujimoto Y, Fulda P, Fyffe M, Gabbard H, Gabella W, Gadre B, Gair J, Gais J, Galaudage S, Gamba R, Ganapathy D, Ganguly A, Gao D, Gaonkar S, Garaventa B, Núñez CG, García-Quirós C, Garufi F, Gateley B, Gayathri V, Ge GG, Gemme G, Gennai A, George J, Gerberding O, Gergely L, Gewecke P, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Ghosh S, Ghosh T, Giacomazzo B, Giacoppo L, Giaime J, Giardina K, Gibson D, Gier C, Giesler M, Giri P, Gissi F, Gkaitatzis S, Glanzer J, Gleckl A, Godwin P, Goetz E, Goetz R, Gohlke N, Golomb J, Goncharov B, González G, Gosselin M, Gouaty R, Gould D, Goyal S, Grace B, Grado A, Graham V, Granata M, Granata V, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green A, Green R, Gretarsson A, Gretarsson E, Griffith D, Griffiths W, Griggs H, Grignani G, Grimaldi A, Grimes E, Grimm S, Grote H, Grunewald S, Gruning P, Gruson A, Guerra D, Guidi G, Guimaraes A, Guixé G, Gulati H, Gunny A, Guo HK, Guo Y, Gupta A, Gupta A, Gupta I, Gupta P, Gupta S, Gustafson R, Guzman F, Ha S, Hadiputrawan I, Haegel L, Haino S, Halim O, Hall E, Hamilton E, Hammond G, Han WB, Haney M, Hanks J, Hanna C, Hannam M, Hannuksela O, Hansen H, Hansen T, Hanson J, Harder T, Haris K, Harms J, Harry G, Harry I, Hartwig D, Hasegawa K, Haskell B, Haster CJ, Hathaway J, Hattori K, Haughian K, Hayakawa H, Hayama K, Hayes F, Healy J, Heidmann A, Heidt A, Heintze M, Heinze J, Heinzel J, Heitmann H, Hellman F, Hello P, Helmling-Cornell A, Hemming G, Hendry M, Heng I, Hennes E, Hennig J, Hennig M, Henshaw C, Hernandez A, Vivanco FH, Heurs M, Hewitt A, Higginbotham S, Hild S, Hill P, Himemoto Y, Hines A, Hirata N, Hirose C, Ho TC, Hochheim S, Hofman D, Hohmann J, Holcomb D, Holland N, Hollows I, Holmes Z, Holt K, Holz D, Hong Q, Hough J, Hourihane S, Howell E, Hoy C, Hoyland D, Hreibi A, Hsieh BH, Hsieh HF, Hsiung C, Hsu Y, Huang HY, Huang P, Huang YC, Huang YJ, Huang Y, Huang Y, Hübner M, Huddart A, Hughey B, Hui D, Hui V, Husa S, Huttner S, Huxford R, Huynh-Dinh T, Ide S, Idzkowski B, Iess A, Inayoshi K, Inoue Y, Iosif P, Isi M, Isleif K, Ito K, Itoh Y, Iyer B, JaberianHamedan V, Jacqmin T, Jacquet PE, Jadhav S, Jadhav S, Jain T, James A, Jan A, Jani K, Janquart J, Janssens K, Janthalur N, Jaranowski P, Jariwala D, Jaume R, Jenkins A, Jenner K, Jeon C, Jia W, Jiang J, Jin HB, Johns G, Johnston R, Jones A, Jones D, Jones P, Jones R, Joshi P, Ju L, Jue A, Jung P, Jung K, Junker J, Juste V, Kaihotsu K, Kajita T, Kakizaki M, Kalaghatgi C, Kalogera V, Kamai B, Kamiizumi M, Kanda N, Kandhasamy S, Kang G, Kanner J, Kao Y, Kapadia S, Kapasi D, Karathanasis C, Karki S, Kashyap R, Kasprzack M, Kastaun W, Kato T, Katsanevas S, Katsavounidis E, Katzman W, Kaur T, Kawabe K, Kawaguchi K, Kéfélian F, Keitel D, Key J, Khadka S, Khalili F, Khan S, Khanam T, Khazanov E, Khetan N, Khursheed M, Kijbunchoo N, Kim A, Kim C, Kim J, Kim J, Kim K, Kim W, Kim YM, Kimball C, Kimura N, Kinley-Hanlon M, Kirchhoff R, Kissel J, Klimenko S, Klinger T, Knee A, Knowles T, Knust N, Knyazev E, Kobayashi Y, Koch P, Koekoek G, Kohri K, Kokeyama K, Koley S, Kolitsidou P, Kolstein M, Komori K, Kondrashov V, Kong A, Kontos A, Koper N, Korobko M, Kovalam M, Koyama N, Kozak D, Kozakai C, Kringel V, Krishnendu N, Królak A, Kuehn G, Kuei F, Kuijer P, Kulkarni S, Kumar A, Kumar P, Kumar R, Kumar R, Kume J, Kuns K, Kuromiya Y, Kuroyanagi S, Kwak K, Lacaille G, Lagabbe P, Laghi D, Lalande E, Lalleman M, Lam T, Lamberts A, Landry M, Lane B, Lang R, Lange J, Lantz B, La Rosa I, Lartaux-Vollard A, Lasky P, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, LeBohec S, Lecoeuche Y, Lee E, Lee H, Lee H, Lee K, Lee R, Legred I, Lehmann J, Lemaître A, Lenti M, Leonardi M, Leonova E, Leroy N, Letendre N, Levesque C, Levin Y, Leviton J, Leyde K, Li A, Li B, Li J, Li K, Li P, Li T, Li X, Lin CY, Lin E, Lin FK, Lin FL, Lin H, Lin LC, Linde F, Linker S, Linley J, Littenberg T, Liu G, Liu J, Liu K, Liu X, Llamas F, Lo R, Lo T, London L, Longo A, Lopez D, Portilla ML, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lott T, Lough J, Lousto C, Lovelace G, Lucaccioni J, Lück H, Lumaca D, Lundgren A, Luo LW, Lynam J, Ma’arif M, Macas R, Machtinger J, MacInnis M, Macleod D, MacMillan I, Macquet A, Hernandez IM, Magazzù C, Magee R, Maggiore R, Magnozzi M, Mahesh S, Majorana E, Maksimovic I, Maliakal S, Malik A, Man N, Mandic V, Mangano V, Mansell G, Manske M, Mantovani M, Mapelli M, Marchesoni F, Pina DM, Marion F, Mark Z, Márka S, Márka Z, Markakis C, Markosyan A, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin I, Martin R, Martinez M, Martinez V, Martinez V, Martinovic K, Martynov D, Marx E, Masalehdan H, Mason K, Massera E, Masserot A, Masso-Reid M, Mastrogiovanni S, Matas A, Mateu-Lucena M, Matichard F, Matiushechkina M, Mavalvala N, McCann J, McCarthy R, McClelland D, McClincy P, McCormick S, McCuller L, McGhee G, McGuire S, McIsaac C, McIver J, McRae T, McWilliams S, Meacher D, Mehmet M, Mehta A, Meijer Q, Melatos A, Melchor D, Mendell G, Menendez-Vazquez A, Menoni C, Mercer R, Mereni L, Merfeld K, Merilh E, Merritt J, Merzougui M, Meshkov S, Messenger C, Messick C, Meyers P, Meylahn F, Mhaske A, Miani A, Miao H, Michaloliakos I, Michel C, Michimura Y, Middleton H, Mihaylov D, Milano L, Miller A, Miller A, Miller B, Millhouse M. Search for continuous gravitational wave emission from the Milky Way center in O3 LIGO-Virgo data. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.042003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
75
|
Yamada T, Masui T, Sasaki M, Katayama M, Iwadate Y, Takei N, Miyoshi M. Time resolved DCE-MRI of the kidneys: Evaluation of the renal vasculatures and tumors using F-DISCO with and without compressed sensing in normal and wide-bore 3T systems. Medicine (Baltimore) 2022; 101:e29971. [PMID: 35945778 PMCID: PMC9351894 DOI: 10.1097/md.0000000000029971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Dynamic contrast-enhanced MR imaging (DCE-MRI) has been widely used for the evaluation of renal arteries. This method is also useful for tumor and renal parenchyma characterization. The very fast MRI may provide stable and precise information regarding vasculature and soft tissues. The purpose of this study was to evaluate the ability of DCE-MRI to assess renal vasculatures and tumor perfusions using Differential subsampling with Cartesian ordering with spectrally selected inversion recovery with adiabatic pulses (F-DISCO) with and without compressed sensing (CS) in normal and wide-bore 3T systems. Fifty-one patients who underwent DCE-MRI using F-DISCO with or without CS for evaluation of renal or adrenal regions were included. Image quality, artifacts, fat saturation, and selective visual recognition of renal vasculatures were assessed by using a 5-point scale. Tumor recognition was verified by using a 5-point scale of confidence level. Signal intensities of each structure were also measured. In all cases, the temporal resolution of each phase for DCE-MRI was 1.9 to 2.0 seconds. Image quality, artifacts, fat saturation, and selective visual recognition of vasculatures were all acceptable (mean score 4.2-4.9). The selective visualization of renal arteries and veins was successfully accomplished (mean score 4.0-4.9). Contrast media perfusion for renal vasculature, renal parenchyma, and tumors was also recognized. DCE-MRI for the evaluation of renal vasculatures and tumors using F-DISCO with or without CS can be performed with high temporal and spatial resolutions in normal and wide-bore 3T systems. This information can be obtained in a stable fashion throughout the dynamic contrast study. CS can additionally provide benefits that the total imaging time may be shorter than without CS.
Collapse
Affiliation(s)
- Takahiro Yamada
- Department of Radiology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
| | - Takayuki Masui
- Department of Radiology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
- *Correspondence: Takayuki Masui, MD, PhD, Seirei Hamamatsu General Hospital, 2-12-12 Sumiyoshi, Naka-district, Hamamatsu, Shizuoka 430-8558, Japan (e-mail )
| | - Masako Sasaki
- Department of Radiology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
| | - Motoyuki Katayama
- Department of Radiology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan
| | - Yuji Iwadate
- Global MR Applications and Workflow, GE Healthcare Japan, Hino, Tokyo, Japan
| | - Naoyuki Takei
- Global MR Applications and Workflow, GE Healthcare Japan, Hino, Tokyo, Japan
| | - Mitsuharu Miyoshi
- Global MR Applications and Workflow, GE Healthcare Japan, Hino, Tokyo, Japan
| |
Collapse
|
76
|
Ukon N, Higashi T, Hosono M, Kinuya S, Yamada T, Yanagida S, Namba M, Nakamura Y. Manual on the proper use of meta-[ 211At] astato-benzylguanidine ([ 211At] MABG) injections in clinical trials for targeted alpha therapy (1st edition). Ann Nucl Med 2022; 36:695-709. [PMID: 35794455 PMCID: PMC9304041 DOI: 10.1007/s12149-022-01765-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 05/24/2022] [Indexed: 11/26/2022]
Abstract
In this manuscript, we present the guideline for use of meta-[211At] astatobenzylguanidine ([211At] MABG), a newly introduced alpha emitting radiopharmaceutical to the up-coming World’s first clinical trial for targeted alpha therapy (TAT) at Fukushima Medical University in Japan, focusing on radiation safety issues in Japan. This guideline was prepared based on a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine on Oct. 5th, 2021. The study showed that patients receiving [211At] MABG do not need to be admitted to a radiotherapy room and that TAT using [211At] MABG is possible on an outpatient basis. The radiation exposure from the patient is within the safety standards of the ICRP and IAEA recommendations for the general public and caregivers or patient’s family members. In this guideline, the following contents are also included: precautions for patients and their families, safety management associated with the use of [211At] MABG, education and training, and disposal of medical radioactive contaminants. TAT using [211At] MABG in Japan should be carried out according to this guideline. Although this guideline is based on the medical environment and laws and regulations in Japan, the issues for radiation protection and evaluation methodology presented in this guideline are useful and internationally acceptable as well.
Collapse
Affiliation(s)
- Naoyuki Ukon
- Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan
| | - Tatsuya Higashi
- Department of Molecular Imaging and Theranostics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, 4-9-1, Anagawa, Inage, Chiba, Chiba, 263-8555, Japan.
| | - Makoto Hosono
- Department of Radiology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan
| | - Seigo Kinuya
- Japanese Society of Nuclear Medicine, 3-1-17 Nishi-Azabu, Minato-ku, Tokyo, 106-0031, Japan
| | - Takahiro Yamada
- Atomic Energy Research Institute, Kindai University, Higashi-Osaka, 3-4-1 Kowakae, Osaka, 577-8502, Japan
| | - Sachiko Yanagida
- Japan Radioisotope Association, 2-28-45 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan
| | - Masao Namba
- Japan Radioisotope Association, 2-28-45 Honkomagome, Bunkyo-ku, Tokyo, 113-0021, Japan
| | - Yoshihide Nakamura
- Chiyoda Technol Corporation, 1-7-12 Yushima, Bunkyo-ku, Tokyo, 113-8681, Japan
| |
Collapse
|
77
|
Yamada T, Hashimoto Y, Tanaka K, Morita N, Tamura O. Cationic palladium(ii)-catalyzed synthesis of substituted pyridines from α,β-unsaturated oxime ethers. RSC Adv 2022; 12:21548-21557. [PMID: 36043185 PMCID: PMC9351437 DOI: 10.1039/d2ra03875g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Accepted: 07/14/2022] [Indexed: 11/21/2022] Open
Abstract
An efficient method for the synthesis of multi-substituted pyridines from β-aryl-substituted α,β-unsaturated oxime ethers and alkenes via Pd-catalyzed C–H activation has been developed. The method, using Pd(OAc)2 and a sterically hindered pyridine ligand, provides access to various multi-substituted pyridines with complete regioselectivity. Mechanistic studies suggest that the pyridine products are formed by Pd-catalyzed electrophilic C–H alkenylation of α,β-unsaturated oxime followed by aza-6π-electrocyclization. The utility of this method is showcased by the synthesis of 4-aryl-substituted pyridine derivatives, which are difficult to synthesize efficiently using previously reported Rh-catalyzed strategies with alkenes. An efficient method for the synthesis of multi-substituted pyridines from α,β-unsaturated oxime ethers via cationic Pd(ii)-catalyzed C–H activation has been developed.![]()
Collapse
Affiliation(s)
- Takahiro Yamada
- Showa Pharmaceutical University Machida Tokyo 194-8543 Japan
| | | | - Kosaku Tanaka
- Showa Pharmaceutical University Machida Tokyo 194-8543 Japan
| | | | - Osamu Tamura
- Showa Pharmaceutical University Machida Tokyo 194-8543 Japan
| |
Collapse
|
78
|
Morioka H, Ohge H, Nagao M, Kato H, Kokado R, Yamada K, Yamada T, Shimono N, Nukui Y, Yoshihara S, Sakamaki I, Nosaka K, Kubo Y, Kawamura H, Fujikura Y, Kitaura T, Sunakawa M, Yagi T. Appropriateness of surgical antimicrobial prophylaxis in Japanese university hospitals. J Hosp Infect 2022; 129:189-197. [PMID: 35835283 DOI: 10.1016/j.jhin.2022.06.017] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 06/15/2022] [Accepted: 06/15/2022] [Indexed: 11/30/2022]
Abstract
OBJECTIVE This study aimed to determine the adherence to the Japanese surgical antimicrobial prophylaxis (SAP) guidelines in Japanese university hospitals. DESIGN A retrospective cohort study. SETTING Fifteen general and one dental university hospitals. METHODS We evaluated up to three cases of 18 designated surgeries regarding adherence to Japanese SAP guidelines: selection of antibiotics, timing of administration, re-dosing intervals, and duration of SAP. When all items were appropriate, surgery was defined as 'appropriate.' RESULTS In total, 688 cases (22-45 cases per surgery) were included. The overall appropriateness was 46.8% (322/688), and the appropriateness of each surgery ranged from 8.0% (2/25, cardiac implantable electronic device implantation) to 92.1% (35/38, distal gastrectomy). The appropriateness of each item was as follows: pre/intraoperative selections, 78.5% (540/688); timing of administrations, 96.0% (630/656); re-dosing intervals, 91.8% (601/656); postoperative selection, 78.9% (543/688); and duration of SAP, 61.4% (423/688). The overall appropriateness of hospitals ranged from 17.6% (9/51) to 73.3% (33/45). The common reasons for inappropriateness were the longer duration (38.5%, 265/688) and choice of antibiotics with a non-optimal antimicrobial spectrum before/during, and after surgery (19.0%, 131/688 and 16.8%, 116/688, respectively), compared to the guideline. CONCLUSIONS Adherence to the guidelines differed greatly between the surgeries and hospitals. Large-scale multicentre surveillance of SAP in Japanese hospitals is necessary to identify inappropriate surgeries, factors related to the appropriateness, and incidences of surgical site infections.
Collapse
Affiliation(s)
- Hiroshi Morioka
- Nagoya University Hospital, Department of Infectious Diseases, Nagoya, Japan.
| | - Hiroki Ohge
- Hiroshima University, Project Research Center for Nosocomial Infectious Diseases, Hiroshima, Japan
| | - Miki Nagao
- Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, Kyoto, Japan
| | - Hideaki Kato
- Yokohama City University Hospital, Infection Prevention and Control Department, Yokohama, Japan
| | - Ryohei Kokado
- Osaka University Hospital, Division of Infection Control and Prevention, Suita, Japan
| | - Koichi Yamada
- Osaka Metropolitan University, Graduate School of Medicine, Department of Infection Control Science, Osaka, Japan
| | - Takahiro Yamada
- Hamamatsu University School of Medicine, Department of Hospital Pharmacy, Hamamatsu, Japan
| | - Nobuyuki Shimono
- Kyushu University Hospital, Center for the Study of Global Infection, Fukuoka, Japan
| | - Yoko Nukui
- Tokyo Medical and Dental University Hospital, Department of Infection Control and Prevention, Bunkyo City, Japan; Kyoto Prefectural University of Medicine, Department of Infection Control and Laboratory Medicine
| | - Shingo Yoshihara
- Nara Medical University, Center for Infectious Diseases, Kashihara, Japan
| | - Ippei Sakamaki
- Toyama University Hospital, Department of Clinical Infectious Diseases, Toyama, Japan
| | - Kisato Nosaka
- Kumamoto University Hospital, Department of Hematology, Rheumatology and Infectious Disease, Kumamoto, Japan
| | - Yuko Kubo
- Hiroshima University Hospital, Department of Pharmaceutical Services, Hiroshima, Japan
| | - Hideki Kawamura
- Kagoshima University Hospital, Department of Infection Control and Prevention, Kagoshima, Japan
| | - Yuji Fujikura
- National Defense Medical College Hospital, Department of Medical Risk Management and Infection Control, Tokorozawa, Japan
| | - Tsuyoshi Kitaura
- Tottori University Hospital, Division of Infectious Diseases, Yonago, Japan
| | - Mitsuhiro Sunakawa
- Tokyo Medical and Dental University, Dental Hospital, Infection Control Team, Tokyo, Japan
| | - Tetsuya Yagi
- Nagoya University Hospital, Department of Infectious Diseases, Nagoya, Japan
| | | |
Collapse
|
79
|
Umemura T, Mutoh Y, Maeda M, Hagihara M, Ohta A, Mizuno T, Kato H, Sukawa M, Yamada T, Ikeda Y, Mikamo H, Ichihara T. Impact of Hospital Environmental Cleaning with a Potassium Peroxymonosulphate-Based Environmental Disinfectant and Antimicrobial Stewardship on the Reduction of Hospital-Onset Clostridioides difficile Infections. J Hosp Infect 2022; 129:181-188. [PMID: 35820556 DOI: 10.1016/j.jhin.2022.06.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Revised: 06/27/2022] [Accepted: 06/29/2022] [Indexed: 11/18/2022]
Abstract
BACKGROUND A 1% potassium peroxymonosulphate-based environmental disinfectant (PPED) produces sodium hypochlorite when combined with sodium chloride, which functions as a disinfectant. However, little is known about the impact of hospital cleaning with PPED on hospital-onset Clostridioides difficile infection (HO-CDI). AIM To reduce HO-CDI, we promote antimicrobial stewardship and hospital ward cleaning with PPED. This study was conducted to evaluate their impact. METHODS We began a promotion of post-prescription review with feedback for broad-spectrum antimicrobials and hospital ward cleaning with PPED. We reviewed the ratio of HO-CDI, PPED consumption, and days of therapy (DOT) of broad-spectrum antimicrobials between July 2014 and March 2018, dividing this time into the pre-promotion (July 2014 to June 2015) and post-promotion periods (July 2015 to March 2018). FINDINGS Using interrupted time series analysis, an immediate significant change in HO-CDI was observed after intervention (P = 0.03), although a downward trend was not observed over this period (P = 0.19). Trends in PPED consumption significantly changed over this period (P = 0.02). DOT of carbapenems decreased immediately after the intervention began (P < 0.01). A Poisson regression analysis showed that PPED consumption and DOT of carbapenems were independent factors affecting HO-CDI (P = 0.039 and 0.016, respectively). CONCLUSION We revealed that DOT of carbapenems and use of PPED were associated with the HO-CDI ratio and that both interventions reduced the rate of HO-CDI. This is the first report on the impact of hospital ward cleaning with PPED on the reduction of HO-CDI.
Collapse
Affiliation(s)
- T Umemura
- Department of Infection and Prevention, Tosei General Hospital, Aichi, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Japan; Department of Pharmacy, Tosei General Hospital, Aichi, Japan; College of Pharmacy, Kinjo Gakuin University, Nagoya, Aichi, Japan.
| | - Y Mutoh
- Department of Infection and Prevention, Tosei General Hospital, Aichi, Japan
| | - M Maeda
- Division of Infection Control Sciences, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan
| | - M Hagihara
- Department of Clinical Infectious Diseases, Aichi Medical University, Japan
| | - A Ohta
- Department of Pharmacy, Tosei General Hospital, Aichi, Japan
| | - T Mizuno
- Department of Pharmacy, Tosei General Hospital, Aichi, Japan
| | - H Kato
- Department of Clinical Infectious Diseases, Aichi Medical University, Japan
| | - M Sukawa
- Department of Infection and Prevention, Tosei General Hospital, Aichi, Japan
| | - T Yamada
- Department of Pharmacy, Tosei General Hospital, Aichi, Japan
| | - Y Ikeda
- College of Pharmacy, Kinjo Gakuin University, Nagoya, Aichi, Japan
| | - H Mikamo
- Department of Clinical Infectious Diseases, Aichi Medical University, Japan
| | - T Ichihara
- Department of Infection and Prevention, Tosei General Hospital, Aichi, Japan
| |
Collapse
|
80
|
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Harada T, Tamiya N, Chihara Y, Hiranuma O, Yamada T, Kanda H, Nakano T, Morimoto Y, Iwasaku M, Tokuda S, Takayama K. Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study. JTO Clin Res Rep 2022; 3:100353. [PMID: 35789793 PMCID: PMC9250020 DOI: 10.1016/j.jtocrr.2022.100353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Revised: 05/17/2022] [Accepted: 05/30/2022] [Indexed: 11/25/2022] Open
Abstract
Introduction To date, the efficacy and safety of programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy for patients with extensive-stage SCLC (ES-SCLC), with real-world evidence, stratified on the basis of age and performance status (PS), have not been fully investigated. The aim of this study was to evaluate the efficacy and safety of PD-L1 inhibitor plus platinum-etoposide chemotherapy in patients with ES-SCLC. Methods This multicenter prospective study evaluated patients with ES-SCLC who received PD-L1 inhibitor plus platinum-etoposide chemotherapy between September 2019 and October 2021. Results A total of 45 patients with ES-SCLC received the aforementioned treatment, including 18 elderly (≥75 y old) patients and six patients with a PS of 2. Multivariate analysis indicated that a PS of 2 was a significant independent prognostic factor for progression-free survival and overall survival (p = 0.008 and p = 0.001, respectively). Of patients with PS of 2 at the initial phase, those that achieved PS improvement during treatment had significantly longer progression-free survival and overall survival than those who did not (p = 0.02 and p = 0.02, respectively). The incidence of adverse events accompanied with treatment discontinuation was significantly higher in the elderly patients than in the non-elderly patients (p = 0.03). Conclusions This real-world prospective study found that PD-L1 inhibitor plus platinum-etoposide chemotherapy had limited efficacy in patients with ES-SCLC with a PS of 2, except for cases with improvement of PS during treatment. Owing to the emergence of adverse events and treatment discontinuation, this treatment should be administered with caution in elderly patients with ES-SCLC.
Collapse
|
81
|
Taylor PH, Yamada T, Striebich RC, Graham JL, Giraud RJ. Corrigendum to "Investigation of waste incineration of fluorotelomer-based polymers as a potential source of PFOA in the environment" [Chemosphere 110 (2014) 17-22]. Chemosphere 2022; 298:134601. [PMID: 35459458 DOI: 10.1016/j.chemosphere.2022.134601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Affiliation(s)
- P H Taylor
- University of Dayton Research Institute, Environmental Engineering Group, 300 College Park, Dayton, OH, 45469, United States.
| | - T Yamada
- University of Dayton Research Institute, Environmental Engineering Group, 300 College Park, Dayton, OH, 45469, United States
| | - R C Striebich
- University of Dayton Research Institute, Environmental Engineering Group, 300 College Park, Dayton, OH, 45469, United States
| | - J L Graham
- University of Dayton Research Institute, Environmental Engineering Group, 300 College Park, Dayton, OH, 45469, United States
| | - R J Giraud
- E.I. du Pont de Nemours and Company, Inc., 1007 Market Street, Wilmington, DE, 19898, United States
| |
Collapse
|
82
|
Yoshioka M, Kondo T, Nguyen QP, Kimura-Tsuchiya R, Fukuyama K, Kanai M, Nakajima T, Yamada T, Matsumoto S, Muto M. MO15-5 A proposal of efficient operation of expert panel for genomic medicine by pre-review meeting (pre-EP). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.05.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
83
|
Yoshioka M, Kanai M, Kondo T, Fukuyama K, Yamamoto Y, Yamanoi K, Kawaguchi-Sakita N, Nomura M, Yokoyama A, Kikuchi O, Matsubara J, Yamada A, Mori Y, Minamiguchi S, Yamada T, Matsumoto S, Muto M. P68-4 Feasibility study of a new tissue-based comprehensive genome profiling test. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.05.335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
84
|
Kamiya A, Yamada T, Yoshida A, Doi T, Okada H. Perinatal management of tension pneumothorax due to cystoamniotic shunt displacement. Congenit Anom (Kyoto) 2022; 62:181-182. [PMID: 35319793 DOI: 10.1111/cga.12467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 01/14/2022] [Accepted: 03/08/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Akio Kamiya
- Department of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Japan
| | - Takahiro Yamada
- Department of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Japan.,Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Kyoto, Japan
| | - Aya Yoshida
- Department of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Japan
| | - Takashi Doi
- Department of Pediatric Surgery, Kansai Medical University, Hirakata, Japan
| | - Hidetaka Okada
- Department of Obstetrics and Gynecology, Kansai Medical University, Hirakata, Japan
| |
Collapse
|
85
|
Yamamuro M, Asai Y, Hashimoto N, Yasuda N, Kimura H, Yamada T, Nemoto M, Kimura Y, Handa H, Yoshida H, Abe K, Tada M, Habe H, Nagaoka T, Nin S, Ishii K, Kondo Y. Utility of U-Net for the objective segmentation of the fibroglandular tissue region on clinical digital mammograms. Biomed Phys Eng Express 2022; 8. [PMID: 35728581 DOI: 10.1088/2057-1976/ac7ada] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 06/21/2022] [Indexed: 11/11/2022]
Abstract
This study investigates the equivalence or compatibility between U-Net and visual segmentations of fibroglandular tissue regions by mammography experts for calculating the breast density and mean glandular dose (MGD). A total of 703 mediolateral oblique-view mammograms were used for segmentation. Two region types were set as the ground truth (determined visually): (1) one type included only the region where fibroglandular tissue was identifiable (called the 'dense region'); (2) the other type included the region where the fibroglandular tissue may have existed in the past, provided that apparent adipose-only parts, such as the retromammary space, are excluded (the 'diffuse region'). U-Net was trained to segment the fibroglandular tissue region with an adaptive moment estimation optimiser, five-fold cross-validated with 400 training and 100 validation mammograms, and tested with 203 mammograms. The breast density and MGD were calculated using the van Engeland and Dance formulas, respectively, and compared between U-Net and the ground truth with the Dice similarity coefficient and Bland-Altman analysis. Dice similarity coefficients between U-Net and the ground truth were 0.895 and 0.939 for the dense and diffuse regions, respectively. In the Bland-Altman analysis, no proportional or fixed errors were discovered in either the dense or diffuse region for breast density, whereas a slight proportional error was discovered in both regions for the MGD (the slopes of the regression lines were -0.0299 and -0.0443 for the dense and diffuse regions, respectively). Consequently, the U-Net and ground truth were deemed equivalent (interchangeable) for breast density and compatible (interchangeable following four simple arithmetic operations) for MGD. U-Net-based segmentation of the fibroglandular tissue region was satisfactory for both regions, providing reliable segmentation for breast density and MGD calculations. U-Net will be useful in developing a reliable individualised screening-mammography programme, instead of relying on the visual judgement of mammography experts.
Collapse
Affiliation(s)
- Mika Yamamuro
- Radiology Center, Kindai University Hospital, 377-2, Ono-higashi, Osaka-sayama, Osaka 589-8511, Japan.,Graduate School of Health Sciences, Niigata University, 2-746, Asahimachidori, Chuouku, Niigata 951-8518, Japan
| | - Yoshiyuki Asai
- Radiology Center, Kindai University Hospital, 377-2, Ono-higashi, Osaka-sayama, Osaka 589-8511, Japan
| | - Naomi Hashimoto
- Radiology Center, Kindai University Hospital, 377-2, Ono-higashi, Osaka-sayama, Osaka 589-8511, Japan
| | - Nao Yasuda
- Radiology Center, Kindai University Hospital, 377-2, Ono-higashi, Osaka-sayama, Osaka 589-8511, Japan
| | - Hiorto Kimura
- Radiology Center, Kindai University Hospital, 377-2, Ono-higashi, Osaka-sayama, Osaka 589-8511, Japan
| | - Takahiro Yamada
- Division of Positron Emission Tomography Institute of Advanced Clinical Medicine, Kindai University, 377-2, Ono-higashi, Osaka-sayama, Osaka 589-8511, Japan
| | - Mitsutaka Nemoto
- Department of Computational Systems Biology, Kindai University Faculty of Biology-Oriented Science and Technology, 930, Nishimitani, Kinokawa, Wakayama 649-6433, Japan
| | - Yuichi Kimura
- Department of Computational Systems Biology, Kindai University Faculty of Biology-Oriented Science and Technology, 930, Nishimitani, Kinokawa, Wakayama 649-6433, Japan
| | - Hisashi Handa
- Department of Informatics, Kindai University Faculty of Science and Engineering, 3-4-1, Kowakae, Higashi-osaka, Osaka 577-8502, Japan
| | - Hisashi Yoshida
- Department of Computational Systems Biology, Kindai University Faculty of Biology-Oriented Science and Technology, 930, Nishimitani, Kinokawa, Wakayama 649-6433, Japan
| | - Koji Abe
- Department of Informatics, Kindai University Faculty of Science and Engineering, 3-4-1, Kowakae, Higashi-osaka, Osaka 577-8502, Japan
| | - Masahiro Tada
- Department of Informatics, Kindai University Faculty of Science and Engineering, 3-4-1, Kowakae, Higashi-osaka, Osaka 577-8502, Japan
| | - Hitoshi Habe
- Department of Informatics, Kindai University Faculty of Science and Engineering, 3-4-1, Kowakae, Higashi-osaka, Osaka 577-8502, Japan
| | - Takashi Nagaoka
- Department of Computational Systems Biology, Kindai University Faculty of Biology-Oriented Science and Technology, 930, Nishimitani, Kinokawa, Wakayama 649-6433, Japan
| | - Seiun Nin
- Department of Radiology, Kindai University Faculty of Medicine, 377-2, Ono-higashi, Osaka-sayama, Osaka 589-8511, Japan
| | - Kazunari Ishii
- Department of Radiology, Kindai University Faculty of Medicine, 377-2, Ono-higashi, Osaka-sayama, Osaka 589-8511, Japan
| | - Yohan Kondo
- Graduate School of Health Sciences, Niigata University, 2-746, Asahimachidori, Chuouku, Niigata 951-8518, Japan
| |
Collapse
|
86
|
Abbott R, Abbott T, Acernese F, Ackley K, Adams C, Adhikari N, Adhikari R, Adya V, Affeldt C, Agarwal D, Agathos M, Agatsuma K, Aggarwal N, Aguiar O, Aiello L, Ain A, Ajith P, Akutsu T, Albanesi S, Allocca A, Altin P, Amato A, Anand C, Anand S, Ananyeva A, Anderson S, Anderson W, Ando M, Andrade T, Andres N, Andrić T, Angelova S, Ansoldi S, Antelis J, Antier S, Appert S, Arai K, Arai K, Arai Y, Araki S, Araya A, Araya M, Areeda J, Arène M, Aritomi N, Arnaud N, Aronson S, Arun K, Asada H, Asali Y, Ashton G, Aso Y, Assiduo M, Aston S, Astone P, Aubin F, Austin C, Babak S, Badaracco F, Bader M, Badger C, Bae S, Bae Y, Baer A, Bagnasco S, Bai Y, Baiotti L, Baird J, Bajpai R, Ball M, Ballardin G, Ballmer S, Balsamo A, Baltus G, Banagiri S, Bankar D, Barayoga J, Barbieri C, Barish B, Barker D, Barneo P, Barone F, Barr B, Barsotti L, Barsuglia M, Barta D, Bartlett J, Barton M, Bartos I, Bassiri R, Basti A, Bawaj M, Bayley J, Baylor A, Bazzan M, Bécsy B, Bedakihale V, Bejger M, Belahcene I, Benedetto V, Moreno G, Mori Y, Morisaki S, Moriwaki Y, Mours B, Mow-Lowry C, Mozzon S, Muciaccia F, Mukherjee A, Mukherjee D, Beniwal D, Mukherjee S, Mukherjee S, Mukherjee S, Mukund N, Mullavey A, Munch J, Muñiz E, Murray P, Musenich R, Muusse S, Bennett T, Nadji S, Nagano K, Nagano S, Nagar A, Nakamura K, Nakano H, Nakano M, Nakashima R, Nakayama Y, Napolano V, Bentley J, Nardecchia I, Narikawa T, Naticchioni L, Nayak B, Nayak R, Negishi R, Neil B, Neilson J, Nelemans G, Nelson T, BenYaala M, Nery M, Neubauer P, Neunzert A, Ng K, Ng S, Nguyen C, Nguyen P, Nguyen T, Quynh LN, Ni WT, Bergamin F, Nichols S, Nishizawa A, Nissanke S, Nitoglia E, Nocera F, Norman M, North C, Nozaki S, Nuttall L, Oberling J, Berger B, O’Brien B, Obuchi Y, O’Dell J, Oelker E, Ogaki W, Oganesyan G, Oh J, Oh K, Oh S, Ohashi M, Bernuzzi S, Ohishi N, Ohkawa M, Ohme F, Ohta H, Okada M, Okutani Y, Okutomi K, Olivetto C, Oohara K, Ooi C, Bersanetti D, Oram R, O’Reilly B, Ormiston R, Ormsby N, Ortega L, O’Shaughnessy R, O’Shea E, Oshino S, Ossokine S, Osthelder C, Bertolini A, Otabe S, Ottaway D, Overmier H, Pace A, Pagano G, Page M, Pagliaroli G, Pai A, Pai S, Palamos J, Betzwieser J, Palashov O, Palomba C, Pan H, Pan K, Panda P, Pang H, Pang P, Pankow C, Pannarale F, Pant B, Beveridge D, Panther F, Paoletti F, Paoli A, Paolone A, Parisi A, Park H, Park J, Parker W, Pascucci D, Pasqualetti A, Bhandare R, Passaquieti R, Passuello D, Patel M, Pathak M, Patricelli B, Patron A, Paul S, Payne E, Pedraza M, Pegoraro M, Bhardwaj U, Pele A, Arellano FP, Penn S, Perego A, Pereira A, Pereira T, Perez C, Périgois C, Perkins C, Perreca A, Bhattacharjee D, Perriès S, Petermann J, Petterson D, Pfeiffer H, Pham K, Phukon K, Piccinni O, Pichot M, Piendibene M, Piergiovanni F, Bhaumik S, Pierini L, Pierro V, Pillant G, Pillas M, Pilo F, Pinard L, Pinto I, Pinto M, Piotrzkowski K, Pirello M, Bilenko I, Pitkin M, Placidi E, Planas L, Plastino W, Pluchar C, Poggiani R, Polini E, Pong D, Ponrathnam S, Popolizio P, Billingsley G, Porter E, Poulton R, Powell J, Pracchia M, Pradier T, Prajapati A, Prasai K, Prasanna R, Pratten G, Principe M, Bini S, Prodi G, Prokhorov L, Prosposito P, Prudenzi L, Puecher A, Punturo M, Puosi F, Puppo P, Pürrer M, Qi H, Birney R, Quetschke V, Quitzow-James R, Raab F, Raaijmakers G, Radkins H, Radulesco N, Raffai P, Rail S, Raja S, Rajan C, Birnholtz O, Ramirez K, Ramirez T, Ramos-Buades A, Rana J, Rapagnani P, Rapol U, Ray A, Raymond V, Raza N, Razzano M, Biscans S, Read J, Rees L, Regimbau T, Rei L, Reid S, Reid S, Reitze D, Relton P, Renzini A, Rettegno P, Bischi M, Rezac M, Ricci F, Richards D, Richardson J, Richardson L, Riemenschneider G, Riles K, Rinaldi S, Rink K, Rizzo M, Biscoveanu S, Robertson N, Robie R, Robinet F, Rocchi A, Rodriguez S, Rolland L, Rollins J, Romanelli M, Romano J, Romano R, Bisht A, Romel C, Romero-Rodríguez A, Romero-Shaw I, Romie J, Ronchini S, Rosa L, Rose C, Rosińska D, Ross M, Rowan S, Biswas B, Rowlinson S, Roy S, Roy S, Roy S, Rozza D, Ruggi P, Ryan K, Sachdev S, Sadecki T, Sadiq J, Bitossi M, Sago N, Saito S, Saito Y, Sakai K, Sakai Y, Sakellariadou M, Sakuno Y, Salafia O, Salconi L, Saleem M, Bizouard MA, Salemi F, Samajdar A, Sanchez E, Sanchez J, Sanchez L, Sanchis-Gual N, Sanders J, Sanuy A, Saravanan T, Sarin N, Blackburn J, Sassolas B, Satari H, Sathyaprakash B, Sato S, Sato T, Sauter O, Savage R, Sawada T, Sawant D, Sawant H, Blair C, Sayah S, Schaetzl D, Scheel M, Scheuer J, Schiworski M, Schmidt P, Schmidt S, Schnabel R, Schneewind M, Schofield R, Blair D, Schönbeck A, Schulte B, Schutz B, Schwartz E, Scott J, Scott S, Seglar-Arroyo M, Sekiguchi T, Sekiguchi Y, Sellers D, Blair R, Sengupta A, Sentenac D, Seo E, Sequino V, Sergeev A, Setyawati Y, Shaffer T, Shahriar M, Shams B, Shao L, Bobba F, Sharma A, Sharma P, Shawhan P, Shcheblanov N, Shibagaki S, Shikauchi M, Shimizu R, Shimoda T, Shimode K, Shinkai H, Bode N, Shishido T, Shoda A, Shoemaker D, Shoemaker D, ShyamSundar S, Sieniawska M, Sigg D, Singer L, Singh D, Singh N, Boer M, Singha A, Sintes A, Sipala V, Skliris V, Slagmolen B, Slaven-Blair T, Smetana J, Smith J, Smith R, Soldateschi J, Bogaert G, Somala S, Somiya K, Son E, Soni K, Soni S, Sordini V, Sorrentino F, Sorrentino N, Sotani H, Soulard R, Boldrini M, Souradeep T, Sowell E, Spagnuolo V, Spencer A, Spera M, Srinivasan R, Srivastava A, Srivastava V, Staats K, Stachie C, Bonavena L, Steer D, Steinlechner J, Steinlechner S, Stops D, Stover M, Strain K, Strang L, Stratta G, Strunk A, Sturani R, Bondu F, Stuver A, Sudhagar S, Sudhir V, Sugimoto R, Suh H, Summerscales T, Sun H, Sun L, Sunil S, Sur A, Bonilla E, Suresh J, Sutton P, Suzuki T, Suzuki T, Swinkels B, Szczepańczyk M, Szewczyk P, Tacca M, Tagoshi H, Tait S, Bonnand R, Takahashi H, Takahashi R, Takamori A, Takano S, Takeda H, Takeda M, Talbot C, Talbot C, Tanaka H, Tanaka K, Booker P, Tanaka K, Tanaka T, Tanaka T, Tanasijczuk A, Tanioka S, Tanner D, Tao D, Tao L, Martín ETS, Taranto C, Boom B, Tasson J, Telada S, Tenorio R, Terhune J, Terkowski L, Thirugnanasambandam M, Thomas M, Thomas P, Thompson J, Thondapu S, Bork R, Thorne K, Thrane E, Tiwari S, Tiwari S, Tiwari V, Toivonen A, Toland K, Tolley A, Tomaru T, Tomigami Y, Boschi V, Tomura T, Tonelli M, Torres-Forné A, Torrie C, e Melo IT, Töyrä D, Trapananti A, Travasso F, Traylor G, Trevor M, Bose N, Tringali M, Tripathee A, Troiano L, Trovato A, Trozzo L, Trudeau R, Tsai D, Tsai D, Tsang K, Tsang T, Bose S, Tsao JS, Tse M, Tso R, Tsubono K, Tsuchida S, Tsukada L, Tsuna D, Tsutsui T, Tsuzuki T, Turbang K, Bossilkov V, Turconi M, Tuyenbayev D, Ubhi A, Uchikata N, Uchiyama T, Udall R, Ueda A, Uehara T, Ueno K, Ueshima G, Boudart V, Unnikrishnan C, Uraguchi F, Urban A, Ushiba T, Utina A, Vahlbruch H, Vajente G, Vajpeyi A, Valdes G, Valentini M, Bouffanais Y, Valsan V, van Bakel N, van Beuzekom M, van den Brand J, Van Den Broeck C, Vander-Hyde D, van der Schaaf L, van Heijningen J, Vanosky J, van Putten M, Bozzi A, van Remortel N, Vardaro M, Vargas A, Varma V, Vasúth M, Vecchio A, Vedovato G, Veitch J, Veitch P, Venneberg J, Bradaschia C, Venugopalan G, Verkindt D, Verma P, Verma Y, Veske D, Vetrano F, Viceré A, Vidyant S, Viets A, Vijaykumar A, Brady P, Villa-Ortega V, Vinet JY, Virtuoso A, Vitale S, Vo T, Vocca H, von Reis E, von Wrangel J, Vorvick C, Vyatchanin S, Bramley A, Wade L, Wade M, Wagner K, Walet R, Walker M, Wallace G, Wallace L, Walsh S, Wang J, Wang J, Branch A, Wang W, Ward R, Warner J, Was M, Washimi T, Washington N, Watchi J, Weaver B, Webster S, Weinert M, Branchesi M, Weinstein A, Weiss R, Weller C, Wellmann F, Wen L, Weßels P, Wette K, Whelan J, White D, Whiting B, Brau J, Whittle C, Wilken D, Williams D, Williams M, Williamson A, Willis J, Willke B, Wilson D, Winkler W, Wipf C, Breschi M, Wlodarczyk T, Woan G, Woehler J, Wofford J, Wong I, Wu C, Wu D, Wu H, Wu S, Wysocki D, Briant T, Xiao L, Xu WR, Yamada T, Yamamoto H, Yamamoto K, Yamamoto K, Yamamoto T, Yamashita K, Yamazaki R, Yang F, Briggs J, Yang L, Yang Y, Yang Y, Yang Z, Yap M, Yeeles D, Yelikar A, Ying M, Yokogawa K, Yokoyama J, Brillet A, Yokozawa T, Yoo J, Yoshioka T, Yu H, Yu H, Yuzurihara H, Zadrożny A, Zanolin M, Zeidler S, Zelenova T, Brinkmann M, Zendri JP, Zevin M, Zhan M, Zhang H, Zhang J, Zhang L, Zhang T, Zhang Y, Zhao C, Zhao G, Brockill P, Zhao Y, Zhao Y, Zhou R, Zhou Z, Zhu X, Zhu ZH, Zucker M, Zweizig J, Brooks A, Brooks J, Brown D, Brunett S, Bruno G, Bruntz R, Bryant J, Bulik T, Bulten H, Buonanno A, Buscicchio R, Buskulic D, Buy C, Byer R, Cadonati L, Cagnoli G, Cahillane C, Bustillo JC, Callaghan J, Callister T, Calloni E, Cameron J, Camp J, Canepa M, Canevarolo S, Cannavacciuolo M, Cannon K, Cao H, Cao Z, Capocasa E, Capote E, Carapella G, Carbognani F, Carlin J, Carney M, Carpinelli M, Carrillo G, Carullo G, Carver T, Diaz JC, Casentini C, Castaldi G, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Ceasar M, Cella G, Cerdá-Durán P, Cesarini E, Chaibi W, Chakravarti K, Subrahmanya SC, Champion E, Chan CH, Chan C, Chan C, Chan K, Chan M, Chandra K, Chanial P, Chao S, Charlton P, Chase E, Chassande-Mottin E, Chatterjee C, Chatterjee D, Chatterjee D, Chaturvedi M, Chaty S, Chen C, Chen H, Chen J, Chen K, Chen X, Chen YB, Chen YR, Chen Z, Cheng H, Cheong C, Cheung H, Chia H, Chiadini F, Chiang CY, Chiarini G, Chierici R, Chincarini A, Chiofalo M, Chiummo A, Cho G, Cho H, Choudhary R, Choudhary S, Christensen N, Chu H, Chu Q, Chu YK, Chua S, Chung K, Ciani G, Ciecielag P, Cieślar M, Cifaldi M, Ciobanu A, Ciolfi R, Cipriano F, Cirone A, Clara F, Clark E, Clark J, Clarke L, Clearwater P, Clesse S, Cleva F, Coccia E, Codazzo E, Cohadon PF, Cohen D, Cohen L, Colleoni M, Collette C, Colombo A, Colpi M, Compton C, Constancio M, Conti L, Cooper S, Corban P, Corbitt T, Cordero-Carrión I, Corezzi S, Corley K, Cornish N, Corre D, Corsi A, Cortese S, Costa C, Cotesta R, Coughlin M, Coulon JP, Countryman S, Cousins B, Couvares P, Coward D, Cowart M, Coyne D, Coyne R, Creighton J, Creighton T, Criswell A, Croquette M, Crowder S, Cudell J, Cullen T, Cumming A, Cummings R, Cunningham L, Cuoco E, Curyło M, Dabadie P, Canton TD, Dall’Osso S, Dálya G, Dana A, DaneshgaranBajastani L, D’Angelo B, Danilishin S, D’Antonio S, Danzmann K, Darsow-Fromm C, Dasgupta A, Datrier L, Datta S, Dattilo V, Dave I, Davier M, Davies G, Davis D, Davis M, Daw E, Dean R, DeBra D, Deenadayalan M, Degallaix J, De Laurentis M, Deléglise S, Del Favero V, De Lillo F, De Lillo N, Del Pozzo W, DeMarchi L, De Matteis F, D’Emilio V, Demos N, Dent T, Depasse A, De Pietri R, De Rosa R, De Rossi C, DeSalvo R, De Simone R, Dhurandhar S, Díaz M, Diaz-Ortiz M, Didio N, Dietrich T, Di Fiore L, Di Fronzo C, Di Giorgio C, Di Giovanni F, Di Giovanni M, Di Girolamo T, Di Lieto A, Ding B, Di Pace S, Di Palma I, Di Renzo F, Divakarla A, Dmitriev A, Doctor Z, D’Onofrio L, Donovan F, Dooley K, Doravari S, Dorrington I, Drago M, Driggers J, Drori Y, Ducoin JG, Dupej P, Durante O, D’Urso D, Duverne PA, Dwyer S, Eassa C, Easter P, Ebersold M, Eckhardt T, Eddolls G, Edelman B, Edo T, Edy O, Effler A, Eguchi S, Eichholz J, Eikenberry S, Eisenmann M, Eisenstein R, Ejlli A, Engelby E, Enomoto Y, Errico L, Essick R, Estellés H, Estevez D, Etienne Z, Etzel T, Evans M, Evans T, Ewing B, Fafone V, Fair H, Fairhurst S, Farah A, Farinon S, Farr B, Farr W, Farrow N, Fauchon-Jones E, Favaro G, Favata M, Fays M, Fazio M, Feicht J, Fejer M, Fenyvesi E, Ferguson D, Fernandez-Galiana A, Ferrante I, Ferreira T, Fidecaro F, Figura P, Fiori I, Fishbach M, Fisher R, Fittipaldi R, Fiumara V, Flaminio R, Floden E, Fong H, Font J, Fornal B, Forsyth P, Franke A, Frasca S, Frasconi F, Frederick C, Freed J, Frei Z, Freise A, Frey R, Fritschel P, Frolov V, Fronzé G, Fujii Y, Fujikawa Y, Fukunaga M, Fukushima M, Fulda P, Fyffe M, Gabbard H, Gadre B, Gair J, Gais J, Galaudage S, Gamba R, Ganapathy D, Ganguly A, Gao D, Gaonkar S, Garaventa B, García-Núñez C, García-Quirós C, Garufi F, Gateley B, Gaudio S, Gayathri V, Ge GG, Gemme G, Gennai A, George J, Gerberding O, Gergely L, Gewecke P, Ghonge S, Ghosh A, Ghosh A, Ghosh S, Ghosh S, Giacomazzo B, Giacoppo L, Giaime J, Giardina K, Gibson D, Gier C, Giesler M, Giri P, Gissi F, Glanzer J, Gleckl A, Godwin P, Goetz E, Goetz R, Gohlke N, Goncharov B, González G, Gopakumar A, Gosselin M, Gouaty R, Gould D, Grace B, Grado A, Granata M, Granata V, Grant A, Gras S, Grassia P, Gray C, Gray R, Greco G, Green A, Green R, Gretarsson A, Gretarsson E, Griffith D, Griffiths W, Griggs H, Grignani G, Grimaldi A, Grimm S, Grote H, Grunewald S, Gruning P, Guerra D, Guidi G, Guimaraes A, Guixé G, Gulati H, Guo HK, Guo Y, Gupta A, Gupta A, Gupta P, Gustafson E, Gustafson R, Guzman F, Ha S, Haegel L, Hagiwara A, Haino S, Halim O, Hall E, Hamilton E, Hammond G, Han WB, Haney M, Hanks J, Hanna C, Hannam M, Hannuksela O, Hansen H, Hansen T, Hanson J, Harder T, Hardwick T, Haris K, Harms J, Harry G, Harry I, Hartwig D, Hasegawa K, Haskell B, Hasskew R, Haster CJ, Hattori K, Haughian K, Hayakawa H, Hayama K, Hayes F, Healy J, Heidmann A, Heidt A, Heintze M, Heinze J, Heinzel J, Heitmann H, Hellman F, Hello P, Helmling-Cornell A, Hemming G, Hendry M, Heng I, Hennes E, Hennig J, Hennig M, Hernandez A, Vivanco FH, Heurs M, Hild S, Hill P, Himemoto Y, Hines A, Hiranuma Y, Hirata N, Hirose E, Hochheim S, Hofman D, Hohmann J, Holcomb D, Holland N, Hollows I, Holmes Z, Holt K, Holz D, Hong Z, Hopkins P, Hough J, Hourihane S, Howell E, Hoy C, Hoyland D, Hreibi A, Hsieh BH, Hsu Y, Huang GZ, Huang HY, Huang P, Huang YC, Huang YJ, Huang Y, Hübner M, Huddart A, Hughey B, Hui D, Hui V, Husa S, Huttner S, Huxford R, Huynh-Dinh T, Ide S, Idzkowski B, Iess A, Ikenoue B, Imam S, Inayoshi K, Ingram C, Inoue Y, Ioka K, Isi M, Isleif K, Ito K, Itoh Y, Iyer B, Izumi K, JaberianHamedan V, Jacqmin T, Jadhav S, Jadhav S, James A, Jan A, Jani K, Janquart J, Janssens K, Janthalur N, Jaranowski P, Jariwala D, Jaume R, Jenkins A, Jenner K, Jeon C, Jeunon M, Jia W, Jin HB, Johns G, Jones A, Jones D, Jones J, Jones P, Jones R, Jonker R, Ju L, Jung P, Jung K, Junker J, Juste V, Kaihotsu K, Kajita T, Kakizaki M, Kalaghatgi C, Kalogera V, Kamai B, Kamiizumi M, Kanda N, Kandhasamy S, Kang G, Kanner J, Kao Y, Kapadia S, Kapasi D, Karat S, Karathanasis C, Karki S, Kashyap R, Kasprzack M, Kastaun W, Katsanevas S, Katsavounidis E, Katzman W, Kaur T, Kawabe K, Kawaguchi K, Kawai N, Kawasaki T, Kéfélian F, Keitel D, Key J, Khadka S, Khalili F, Khan S, Khazanov E, Khetan N, Khursheed M, Kijbunchoo N, Kim C, Kim J, Kim J, Kim K, Kim W, Kim YM, Kimball C, Kimura N, Kinley-Hanlon M, Kirchhoff R, Kissel J, Kita N, Kitazawa H, Kleybolte L, Klimenko S, Knee A, Knowles T, Knyazev E, Koch P, Koekoek G, Kojima Y, Kokeyama K, Koley S, Kolitsidou P, Kolstein M, Komori K, Kondrashov V, Kong A, Kontos A, Koper N, Korobko M, Kotake K, Kovalam M, Kozak D, Kozakai C, Kozu R, Kringel V, Krishnendu N, Królak A, Kuehn G, Kuei F, Kuijer P, Kumar A, Kumar P, Kumar R, Kumar R, Kume J, Kuns K, Kuo C, Kuo HS, Kuromiya Y, Kuroyanagi S, Kusayanagi K, Kuwahara S, Kwak K, Lagabbe P, Laghi D, Lalande E, Lam T, Lamberts A, Landry M, Lane B, Lang R, Lange J, Lantz B, La Rosa I, Lartaux-Vollard A, Lasky P, Laxen M, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lecoeuche Y, Lee H, Lee H, Lee H, Lee J, Lee K, Lee R, Lehmann J, Lemaître A, Leonardi M, Leroy N, Letendre N, Levesque C, Levin Y, Leviton J, Leyde K, Li A, Li B, Li J, Li K, Li T, Li X, Lin CY, Lin FK, Lin FL, Lin H, Lin LCC, Linde F, Linker S, Linley J, Littenberg T, Liu G, Liu J, Liu K, Liu X, Llamas F, Llorens-Monteagudo M, Lo R, Lockwood A, London L, Longo A, Lopez D, Portilla ML, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lott T, Lough J, Lousto C, Lovelace G, Lucaccioni J, Lück H, Lumaca D, Lundgren A, Luo LW, Lynam J, Macas R, MacInnis M, Macleod D, MacMillan I, Macquet A, Hernandez IM, Magazzù C, Magee R, Maggiore R, Magnozzi M, Mahesh S, Majorana E, Makarem C, Maksimovic I, Maliakal S, Malik A, Man N, Mandic V, Mangano V, Mango J, Mansell G, Manske M, Mantovani M, Mapelli M, Marchesoni F, Marchio M, Marion F, Mark Z, Márka S, Márka Z, Markakis C, Markosyan A, Markowitz A, Maros E, Marquina A, Marsat S, Martelli F, Martin I, Martin R, Martinez M, Martinez V, Martinez V, Martinovic K, Martynov D, Marx E, Masalehdan H, Mason K, Massera E, Masserot A, Massinger T, Masso-Reid M, Mastrogiovanni S, Matas A, Mateu-Lucena M, Matichard F, Matiushechkina M, Mavalvala N, McCann J, McCarthy R, McClelland D, McClincy P, McCormick S, McCuller L, McGhee G, McGuire S, McIsaac C, McIver J, McRae T, McWilliams S, Meacher D, Mehmet M, Mehta A, Meijer Q, Melatos A, Melchor D, Mendell G, Menendez-Vazquez A, Menoni C, Mercer R, Mereni L, Merfeld K, Merilh E, Merritt J, Merzougui M, Meshkov S, Messenger C, Messick C, Meyers P, Meylahn F, Mhaske A, Miani A, Miao H, Michaloliakos I, Michel C, Michimura Y, Middleton H, Milano L, Miller A, Miller A, Miller B, Millhouse M, Mills J, Milotti E, Minazzoli O, Minenkov Y, Mio N, Mir L, Miravet-Tenés M, Mishra C, Mishra T, Mistry T, Mitra S, Mitrofanov V, Mitselmakher G, Mittleman R, Miyakawa O, Miyamoto A, Miyazaki Y, Miyo K, Miyoki S, Mo G, Moguel E, Mogushi K, Mohapatra S, Mohite S, Molina I, Molina-Ruiz M, Mondin M, Montani M, Moore C, Moraru D, Morawski F, More A, Moreno C. All-sky, all-frequency directional search for persistent gravitational waves from Advanced LIGO’s and Advanced Virgo’s first three observing runs. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.105.122001] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
87
|
Yamada T, Miura T, Sakamoto Y, Morohashi H, Kagiya T, Ogasawara H, Kubota S, Yamamoto T, Hakamada K. [Treatment Strategy for Stage Ⅳ Rectal Cancer Considering Local Treatment Outcomes]. Gan To Kagaku Ryoho 2022; 49:683-686. [PMID: 35799396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
We investigated 36 patients with Stage Ⅳ rectal cancer who underwent primary resection in our department between November 2015 and June 2020. Tumor localization was upper in 20 cases and lower in 16 cases. Six patients had the cT4b stage at initial diagnosis, and lateral lymph node metastases were detected in 6 cases. Preoperative treatment consisted of doublet chemotherapy in 20 cases, in combination with bevacizumab in 17 cases. Surgery for distant metastases was performed in 21 patients, and the final results were curative(Cur B)in 20 patients and palliative(Cur C)in 16 patients. Perioperative mortality was observed only in Cur C patients(5.6%). The local R1 resection rates in Cur B and Cur C patients were 10.0% and 18.8%, respectively, and the corresponding local RM≤1 mm rates were 55.0% and 43.8%. Additionally, the local recurrence rates were 25.0% and 0%, and the 3-year OS rates were 80.9% and 25.5%, respectively, in Cur B and Cur C patients. In Cur B, the local RM≤1 mm rates in the preoperative and non-preoperative treatment groups were 38.5% and 85.7%, respectively, and the corresponding local R1 resection rates were 7.7% and 14.3%. Additionally, the 3-year local recurrence-free survival rates were 68.2% and 66.7% and the 3-year OS rates were 82.1% and 80.0%, respectively, in the preoperative and non-preoperative treatment groups. We determined that preoperative chemotherapy alone is not sufficient for the local treatment of Stage Ⅳ rectal cancer, and concomitant preoperative radiotherapy should be considered. The prognosis of patients with Cur C is poor, and surgery-related deaths have been observed, which can be a problem for the palliative resection strategy.
Collapse
Affiliation(s)
- Takahiro Yamada
- Dept. of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine
| | | | | | | | | | | | | | | | | |
Collapse
|
88
|
Matsuoka H, Narita Y, Misumi T, Sakamoto Y, Kawakami T, Tanioka H, Matsushima T, Miwa H, Shoji H, Ishiguro A, Fushida S, Miura K, Yamada T, Shinozaki K, Mizukami T, Moriwaki T, Mitani S, Nakamura M, Muro K, Nishina T. P-61 Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
89
|
Kondo T, Yamamoto Y, Fukuyama K, Kanai M, Yamada A, Matsubara J, Quy PN, Yoshioka M, Yamada T, Minamiguchi S, Matsumoto S, Kosugi S, Muto M. Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling. Int J Clin Oncol 2022; 27:1256-1263. [PMID: 35567649 DOI: 10.1007/s10147-022-02176-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Accepted: 04/17/2022] [Indexed: 12/25/2022]
Abstract
BACKGROUND The European Society for Medical Oncology Precision Medicine Working Group (ESMO-PMWG) published recommendations regarding confirmatory germline testing for presumed germline pathogenic variants (PGPVs) in tumor-only comprehensive genomic profiling (CGP). However, the clinical validity of these recommendations has not been investigated in a real-world practice. METHODS Medical records of 180 consecutive patients who obtained the results of a tumor-only CGP (FoundationOne® CDx, Foundation Medicine, Inc, Cambridge, MA, USA) between October 2018 and March 2020, were retrospectively reviewed. After excluding patients with no reported variants in 45 actionable genes (n = 6), or no archived germline DNA samples (n = 31), 143 patients were investigated. The PGPVs were selected from the CGP report and germline sequencing were performed using DNA samples archived in Clinical Bioresource Center in Kyoto University Hospital (Kyoto, Japan). RESULTS A total of 195 variants were classified as PGPV based on the conventional criteria. Germline sequencing disclosed that 12 variants (6.2%) were of germline origin. In contrast, after filtering these 195 variants through the ESMO-PMWG recommendation criteria for confirmatory germline testing, following seven PGPVs, BRCA2 (n = 2), BRIP1 (n = 1), BAP1 (n = 1), PMS2 (n = 1), MSH2 (n = 1), and SDHB (n = 1) remained and six variants (85.7%) were confirmed to be of germline origin. CONCLUSION Our current data suggested that the application of ESMO-PMWG criteria is helpful in selecting PGPVs with a high likelihood of germline origin in a tumor-only CGP in daily clinical practice.
Collapse
Affiliation(s)
- Tomohiro Kondo
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.,Research Fellow of Japan Society for the Promotion of Science, 5-3-1 Kojimachi, Chiyoda-ku, Tokyo, 102-0083, Japan.,Clinical Genetics Unit, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Yoshihiro Yamamoto
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Keita Fukuyama
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Masashi Kanai
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
| | - Atsushi Yamada
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Junichi Matsubara
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Pham Nguyen Quy
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Masahiro Yoshioka
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.,Clinical Genetics Unit, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Takahiro Yamada
- Clinical Genetics Unit, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.,Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan
| | - Sachiko Minamiguchi
- Department of Diagnostic Pathology, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Shigemi Matsumoto
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Shinji Kosugi
- Clinical Genetics Unit, Kyoto University Hospital, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.,Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Yoshida-Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan
| | - Manabu Muto
- Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
| |
Collapse
|
90
|
Yamada T, Hattori H, Kikuchi N, Haruki S, Minami Y, Ichihara Y, Saito S, Nunoda S, Niinami H, Hagiwara N. Acute myocardial infarction and sudden cardiac arrest caused by anomalous left coronary artery arising from the noncoronary cusp. J Cardiol Cases 2022; 25:312-315. [PMID: 35582076 PMCID: PMC9091523 DOI: 10.1016/j.jccase.2021.11.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Revised: 10/23/2021] [Accepted: 11/22/2021] [Indexed: 10/19/2022] Open
Abstract
Anomalous left coronary artery arising from the noncoronary cusp (LCANCC) is a rare congenital disorder. We herein describe a 17-year-old female patient with sudden cardiac arrest followed by refractory cardiogenic shock. LCANCC-induced acute myocardial infarction with left main coronary artery involvement was subsequently diagnosed, and the patient required a durable left ventricular assist device. .
Collapse
Affiliation(s)
- Takahiro Yamada
- Department of Cardiology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
| | - Hidetoshi Hattori
- Department of Cardiology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
| | - Noriko Kikuchi
- Department of Cardiology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
| | - Shintaro Haruki
- Department of Cardiology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
| | - Yuichiro Minami
- Department of Cardiology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
| | - Yuki Ichihara
- Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Satoshi Saito
- Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Shinichi Nunoda
- Department of Therapeutic Strategy for Severe Heart Failure, Graduate School of Medicine, Tokyo Women's Medical University, Tokyo, Japan
| | - Hiroshi Niinami
- Department of Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan
| | - Nobuhisa Hagiwara
- Department of Cardiology, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
| |
Collapse
|
91
|
Maekawa M, Maekawa T, Sasase T, Takagi K, Takeuchi S, Kitamoto M, Nakagawa T, Toyoda K, Konishi N, Ohta T, Yamada T. Pathophysiological Analysis of Uninephrectomized db/db Mice as a Model of Severe Diabetic Kidney Disease. Physiol Res 2022; 71:209-217. [DOI: 10.33549/physiolres.934784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Diabetic nephropathy, included in diabetic kidney disease (DKD), is the primary disease leading to end-stage renal disease (ESRD) or dialysis treatment, accounting for more than 40% of all patients with ESRD or receiving dialysis. Developing new therapeutics to prevent the transition to ESRD or dialysis treatment requires an understanding of the pathophysiology of DKD and an appropriate animal model for drug efficacy studies. In this study, we investigated the pathophysiology of diabetic kidney disease with type 2 diabetes in uninephrectomized db/db mice. In addition, the nephrectomized db/db mice from 10 weeks to 42 weeks were used to assess the efficacy of long-term administration of the angiotensin-II–receptor antagonist losartan. The blood and urinary biochemical parameters and the blood pressure which is a main pharmacological endpoint of the losartan therapy, were periodically measured. And at the end, histopathological analysis was performed. Uninephrectomized db/db mice clearly developed obesity and hyperglycemia from young age. Furthermore, they showed renal pathophysiological changes, such as increased urinary albumin-creatinine ratio (UACR) (the peak value 3104±986 in 40-week-old mice), glomerular hypertrophy and increased fibrotic areas in the tubulointerstitial tubules. The blood pressure in the losartan group was significantly low compared to the normotensive Vehicle group. However, as expected, Losartan suppressed the increase in UACR (829±500) indicating the medication was sufficient, but the histopathological abnormalities including tubular interstitial fibrosis did not improve. These results suggest that the uninephrectomized db/db mice are useful as an animal model of the severe DKD indicated by the comparison of the efficacy of losartan in this model with the efficacy of losartan in clinical practice.
Collapse
Affiliation(s)
| | - T Maekawa
- Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
92
|
Miura T, Sakamoto Y, Morohashi H, Suto A, Kubota S, Ichisawa A, Kuwata D, Yamada T, Tamba H, Matsumoto S, Hakamada K. Robotic surgery contributes to the preservation of bowel and urinary function after total mesorectal excision: comparisons with transanal and conventional laparoscopic surgery. BMC Surg 2022; 22:147. [PMID: 35449005 PMCID: PMC9026934 DOI: 10.1186/s12893-022-01596-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 04/11/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Determine whether robotic surgery is more effective than transanal and conventional laparoscopic surgery in preserving bowel and urinary function after total mesorectal excision (TME). METHODS Of 79 lower rectal cancer patients who underwent function-preserving TME between 2016 and 2020, 64 patients consented to a prospective questionnaire-based functional observation study (52 responded). At 6 months post-resection or ileostomy closure, Wexner, low anterior resection syndrome (LARS), modified fecal incontinence quality of life, and international prostate symptom scores were used to evaluate bowel and urinary function, comparing robotic surgery (RTME) with transanal (taTME) or conventional laparoscopic surgery (LTME). RESULTS RTME was performed in 35 patients (54.7%), taTME in 15 (23.4%), and LTME in 14 (21.9%). While preoperative bowel/urinary functions were similar in all three procedures, and the distance from the anal verge to tumor was almost the same, more hand-sewn anastomoses were performed and the anastomotic height from the anal verge was shorter in taTME than RTME. At 2 years post-resection, 8 patients (12.5%) had a permanent stoma; RTME showed a significantly lower rate of permanent stoma than taTME (2.9% vs. 40%, p < 0.01). Despite no significant difference, all bowel function assessments were better in RTME than in taTME or LTME. Major LARS was observed in all taTME and LTME cases, but only 78.8% of RTME. No clear difference arose between RTME and taTME in urinary function; urinary dysfunction was more severe in LTME than RTME (36.4% vs. 6.1%, p = 0.02). CONCLUSIONS In function-preserving TME for lower rectal cancer, robotic surgery was suggested to be more effective than transanal and conventional laparoscopic surgery in terms of bowel and urinary functions.
Collapse
Affiliation(s)
- Takuya Miura
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan.
| | - Yoshiyuki Sakamoto
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Hajime Morohashi
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Akiko Suto
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Shunsuke Kubota
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Aika Ichisawa
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Daisuke Kuwata
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Takahiro Yamada
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Hiroaki Tamba
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Shuntaro Matsumoto
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| | - Kenichi Hakamada
- Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Zaifu-cho 5, Hirosaki, 036-8562, Japan
| |
Collapse
|
93
|
Tachibana S, Sawada H, Okazaki R, Takano Y, Sakamoto K, Miura YN, Okamoto C, Yano H, Yamanouchi S, Michel P, Zhang Y, Schwartz S, Thuillet F, Yurimoto H, Nakamura T, Noguchi T, Yabuta H, Naraoka H, Tsuchiyama A, Imae N, Kurosawa K, Nakamura AM, Ogawa K, Sugita S, Morota T, Honda R, Kameda S, Tatsumi E, Cho Y, Yoshioka K, Yokota Y, Hayakawa M, Matsuoka M, Sakatani N, Yamada M, Kouyama T, Suzuki H, Honda C, Yoshimitsu T, Kubota T, Demura H, Yada T, Nishimura M, Yogata K, Nakato A, Yoshitake M, Suzuki AI, Furuya S, Hatakeda K, Miyazaki A, Kumagai K, Okada T, Abe M, Usui T, Ireland TR, Fujimoto M, Yamada T, Arakawa M, Connolly HC, Fujii A, Hasegawa S, Hirata N, Hirata N, Hirose C, Hosoda S, Iijima Y, Ikeda H, Ishiguro M, Ishihara Y, Iwata T, Kikuchi S, Kitazato K, Lauretta DS, Libourel G, Marty B, Matsumoto K, Michikami T, Mimasu Y, Miura A, Mori O, Nakamura-Messenger K, Namiki N, Nguyen AN, Nittler LR, Noda H, Noguchi R, Ogawa N, Ono G, Ozaki M, Senshu H, Shimada T, Shimaki Y, Shirai K, Soldini S, Takahashi T, Takei Y, Takeuchi H, Tsukizaki R, Wada K, Yamamoto Y, Yoshikawa K, Yumoto K, Zolensky ME, Nakazawa S, Terui F, Tanaka S, Saiki T, Yoshikawa M, Watanabe S, Tsuda Y. Pebbles and sand on asteroid (162173) Ryugu: In situ observation and particles returned to Earth. Science 2022; 375:1011-1016. [PMID: 35143255 DOI: 10.1126/science.abj8624] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The Hayabusa2 spacecraft investigated the C-type (carbonaceous) asteroid (162173) Ryugu. The mission performed two landing operations to collect samples of surface and subsurface material, the latter exposed by an artificial impact. We present images of the second touchdown site, finding that ejecta from the impact crater was present at the sample location. Surface pebbles at both landing sites show morphological variations ranging from rugged to smooth, similar to Ryugu's boulders, and shapes from quasi-spherical to flattened. The samples were returned to Earth on 6 December 2020. We describe the morphology of >5 grams of returned pebbles and sand. Their diverse color, shape, and structure are consistent with the observed materials of Ryugu; we conclude that they are a representative sample of the asteroid.
Collapse
Affiliation(s)
- S Tachibana
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan.,Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Sawada
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - R Okazaki
- Department of Earth and Planetary Sciences, Kyushu University, Fukuoka 812-8581, Japan
| | - Y Takano
- Biogeochemistry Research Center, Japan Agency for Marine-Earth Science and Technology, Kanagawa 237-0061, Japan
| | - K Sakamoto
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan.,Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y N Miura
- Earthquake Research Institute, The University of Tokyo, Tokyo 113-0032, Japan
| | - C Okamoto
- Department of Planetology, Kobe University, Kobe 657-8501, Japan
| | - H Yano
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Yamanouchi
- Department of Earth and Planetary Sciences, Kyushu University, Fukuoka 812-8581, Japan
| | - P Michel
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre national de la recherche scientifique, Laboratoire Lagrange, F-06304 Nice CEDEX 4, France
| | - Y Zhang
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre national de la recherche scientifique, Laboratoire Lagrange, F-06304 Nice CEDEX 4, France
| | - S Schwartz
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ 85705, USA.,Planetary Science Institute, Tucson, AZ 85719, USA
| | - F Thuillet
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre national de la recherche scientifique, Laboratoire Lagrange, F-06304 Nice CEDEX 4, France
| | - H Yurimoto
- Department of Earth and Planetary Sciences, Hokkaido University, Sapporo 060-0810, Japan
| | - T Nakamura
- Department of Earth Sciences, Tohoku University, Sendai 980-8578, Japan
| | - T Noguchi
- Department of Earth and Planetary Sciences, Kyushu University, Fukuoka 812-8581, Japan.,Division of Earth and Planetary Sciences, Kyoto University, Kyoto, Japan
| | - H Yabuta
- Department of Earth and Planetary Systems Science, Hiroshima University, Higashi-Hiroshima 739-8526, Japan
| | - H Naraoka
- Department of Earth and Planetary Sciences, Kyushu University, Fukuoka 812-8581, Japan
| | - A Tsuchiyama
- Research Organization of Science and Technology, Ritsumeikan University, Kusatsu 525-8577, Japan.,Guangzhou Institute of Geochemistry, Chinese Academy of Sciences, Guangzhou 510640, China
| | - N Imae
- Polar Science Resources Center, National Institute of Polar Research, Tokyo 190-8518, Japan
| | - K Kurosawa
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - A M Nakamura
- Department of Planetology, Kobe University, Kobe 657-8501, Japan
| | - K Ogawa
- JAXA Space Exploration Center, JAXA, Sagamihara 252-5210, Japan
| | - S Sugita
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - T Morota
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - R Honda
- Department of Information Science, Kochi University, Kochi 780-8520, Japan
| | - S Kameda
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - E Tatsumi
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan.,Instituto de Astrofísica de Canarias, University of La Laguna, E-38205 Tenerife, Spain
| | - Y Cho
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - K Yoshioka
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - Y Yokota
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Hayakawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Matsuoka
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N Sakatani
- Department of Physics, Rikkyo University, Tokyo 171-8501, Japan
| | - M Yamada
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - T Kouyama
- Information Technology and Human Factors, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan
| | - H Suzuki
- Department of Physics, Meiji University, Kawasaki 214-8571, Japan
| | - C Honda
- Aizu Research Center for Space Informatics, University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - T Yoshimitsu
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Kubota
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Demura
- Aizu Research Center for Space Informatics, University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - T Yada
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Nishimura
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Yogata
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - A Nakato
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Yoshitake
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - A I Suzuki
- Marine Works Japan Ltd., Yokosuka 237-0063, Japan.,Department of Economics, Toyo University, Tokyo 112-8606, Japan
| | - S Furuya
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan.,Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Hatakeda
- Marine Works Japan Ltd., Yokosuka 237-0063, Japan
| | - A Miyazaki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Kumagai
- Marine Works Japan Ltd., Yokosuka 237-0063, Japan
| | - T Okada
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Abe
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Space and Astronautical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - T Usui
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T R Ireland
- School of Earth and Environmental Sciences, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - M Fujimoto
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - T Yamada
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Arakawa
- Department of Planetology, Kobe University, Kobe 657-8501, Japan
| | - H C Connolly
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ 85705, USA.,Department of Geology, Rowan University, Glassboro, NJ 08028, USA
| | - A Fujii
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Hasegawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - N Hirata
- Aizu Research Center for Space Informatics, University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - N Hirata
- Department of Planetology, Kobe University, Kobe 657-8501, Japan
| | - C Hirose
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - S Hosoda
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - Y Iijima
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - H Ikeda
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Ishiguro
- Department of Physics and Astronomy, Seoul National University, Seoul 08826, Korea
| | - Y Ishihara
- JAXA Space Exploration Center, JAXA, Sagamihara 252-5210, Japan
| | - T Iwata
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Space and Astronautical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - S Kikuchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - K Kitazato
- Aizu Research Center for Space Informatics, University of Aizu, Aizu-Wakamatsu 965-8580, Japan
| | - D S Lauretta
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ 85705, USA
| | - G Libourel
- Université Côte d'Azur, Observatoire de la Côte d'Azur, Centre national de la recherche scientifique, Laboratoire Lagrange, F-06304 Nice CEDEX 4, France
| | - B Marty
- Université de Lorraine, Centre national de la recherche scientifique, Centre de Recherches Pétrographiques et Géochimiques, F-54000 Nancy, France
| | - K Matsumoto
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,Department of Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - T Michikami
- Department of Mechanical Engineering, Kindai University, Higashi-Hiroshima 739-2116, Japan
| | - Y Mimasu
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - A Miura
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Space and Astronautical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - O Mori
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | | | - N Namiki
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,Department of Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - A N Nguyen
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - L R Nittler
- Carnegie Institution for Science, Washington, DC 20015, USA
| | - H Noda
- National Astronomical Observatory of Japan, Mitaka 181-8588, Japan.,Department of Astronomical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - R Noguchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Science, Niigata University, Niigata 950-2181, Japan
| | - N Ogawa
- JAXA Space Exploration Center, JAXA, Sagamihara 252-5210, Japan
| | - G Ono
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - M Ozaki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Space and Astronautical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - H Senshu
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - T Shimada
- JAXA Space Exploration Center, JAXA, Sagamihara 252-5210, Japan
| | - Y Shimaki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Shirai
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Soldini
- Department of Mechanical, Materials and Aerospace Engineering, University of Liverpool, Liverpool L69 3BX, UK
| | | | - Y Takei
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - H Takeuchi
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Space and Astronautical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - R Tsukizaki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - K Wada
- Planetary Exploration Research Center, Chiba Institute of Technology, Narashino 275-0016, Japan
| | - Y Yamamoto
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Space and Astronautical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - K Yoshikawa
- Research and Development Directorate, JAXA, Sagamihara 252-5210, Japan
| | - K Yumoto
- UTokyo Organization for Planetary and Space Science-Department of Earth and Planetary Science, The University of Tokyo, Tokyo 113-0033, Japan
| | - M E Zolensky
- NASA Johnson Space Center, Houston, TX 77058, USA
| | - S Nakazawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - F Terui
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - S Tanaka
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Space and Astronautical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - T Saiki
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan
| | - M Yoshikawa
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Space and Astronautical Science, The Graduate University for Advanced Studies, SOKENDAI, Hayama 240-0193, Japan
| | - S Watanabe
- Department of Earth and Environmental Sciences, Nagoya University, Nagoya 464-8601, Japan
| | - Y Tsuda
- Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency (JAXA), Sagamihara 252-5210, Japan.,Department of Aeronautics and Astronautics, The University of Tokyo, Tokyo 113-0033, Japan
| |
Collapse
|
94
|
John JD, Nishimoto S, Kadowaki N, Saito I, Okano K, Okano S, Zahn DRT, Masuzawa T, Yamada T, Chua DHC, Ito T. Quantum device designing (QDD) for future semiconductor engineering. Rev Sci Instrum 2022; 93:034703. [PMID: 35365006 DOI: 10.1063/5.0081544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/09/2021] [Accepted: 02/21/2022] [Indexed: 06/14/2023]
Abstract
In semiconductor device history, a trend is observed where narrowing and increasing the number of material layers improve device functionality, with diodes, transistors, thyristors, and superlattices following this trend. While superlattices promise unique functionality, they are not widely adopted due to a technology barrier, requiring advanced fabrication, such as molecular beam epitaxy and lattice-matched materials. Here, a method to design quantum devices using amorphous materials and physical vapor deposition is presented. It is shown that the multiplication gain M depends on the number of layers of the superlattice, N, as M = kN, with k as a factor indicating the efficiency of multiplication. This M is, however, a trade-off with transit time, which also depends on N. To demonstrate, photodetector devices are fabricated on Si, with the superlattice of Se and As2Se3, and characterized using current-voltage (I-V) and current-time (I-T) measurements. For superlattices with the total layer thicknesses of 200 nm and 2 μm, the results show that k200nm = 0.916 and k2μm = 0.384, respectively. The results confirm that the multiplication factor is related to the number of superlattice layers, showing the effectiveness of the design approach.
Collapse
Affiliation(s)
- J D John
- Department of Physics, International Christian University, 3-10-2 Osawa, Mitaka, Tokyo 181-8585, Japan
| | - S Nishimoto
- Department of Physics, International Christian University, 3-10-2 Osawa, Mitaka, Tokyo 181-8585, Japan
| | - N Kadowaki
- Department of Physics, International Christian University, 3-10-2 Osawa, Mitaka, Tokyo 181-8585, Japan
| | - I Saito
- Department of Physics, International Christian University, 3-10-2 Osawa, Mitaka, Tokyo 181-8585, Japan
| | - K Okano
- Department of Physics, International Christian University, 3-10-2 Osawa, Mitaka, Tokyo 181-8585, Japan
| | - S Okano
- Semiconductor Physics, Chemnitz University of Technology, D-09107 Chemnitz, Germany
| | - D R T Zahn
- Semiconductor Physics, Chemnitz University of Technology, D-09107 Chemnitz, Germany
| | - T Masuzawa
- Research Institute of Electronics, Shizuoka University, 3-5-1 Johoku, Naka-ku, Hamamatsu 432-8011, Japan
| | - T Yamada
- Nanomaterials Research Institute, National Institute of Advanced Industrial Science and Technology, 1-1-1 Higashi, Tsukuba 305-8565, Japan
| | - D H C Chua
- Department of Material Science and Engineering, National University of Singapore, 9 Engineering Drive, Singapore 119077
| | - T Ito
- Eiwa Bussan Company Limited, 2-9-14 Uchikanda, Chiyoda-ku, Tokyo, Japan
| |
Collapse
|
95
|
Yamaguchi Y, Yamada T, Goto M, Kawasaki H, Wada T, Ikeda-Sakai Y, Saito Y, Hayashi M, Tanaka S, Takahashi R, Nakayama T, Murashima A, Kosugi S. Analysis of triptan use during pregnancy in Japan: A case series. Congenit Anom (Kyoto) 2022; 62:78-81. [PMID: 34981573 DOI: 10.1111/cga.12456] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Revised: 11/27/2021] [Accepted: 12/06/2021] [Indexed: 11/26/2022]
Abstract
To evaluate the safety of triptan use during pregnancy in a Japanese population, we descriptively analyzed the data on pregnancy and fetal outcomes from 128 pregnant women using triptans for migraine treatment at two Japanese facilities that provided counseling on drug exposure in pregnancy between 2001 and 2017. The risks of miscarriage, low birth weight, and preterm birth were similar to those reported in the demographic statistics in Japan. The incidence proportion of malformation was also within the baseline risk range. Accumulated data suggest that exposure to triptans during pregnancy does not clearly increase the risk of negative pregnancy and fetal outcomes. This finding can help reduce anxiety in pregnant women with migraines who are taking triptans.
Collapse
Affiliation(s)
- Yuko Yamaguchi
- Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Kyoto, Japan.,Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takahiro Yamada
- Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Kyoto, Japan
| | - Mikako Goto
- National Center for Child Health and Development, The Japan Drug Information Institute in Pregnancy, Tokyo, Japan
| | - Hidenori Kawasaki
- Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Kyoto, Japan
| | - Takahito Wada
- Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Kyoto, Japan
| | - Yasuko Ikeda-Sakai
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan.,Department of Health Informatics, Graduate School of Medicine and School of Public Health, Kyoto University, Kyoto, Japan
| | - Yoshiyuki Saito
- Department of Health Informatics, Graduate School of Medicine and School of Public Health, Kyoto University, Kyoto, Japan
| | | | - Shiro Tanaka
- Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Ryosuke Takahashi
- Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Takeo Nakayama
- Department of Health Informatics, Graduate School of Medicine and School of Public Health, Kyoto University, Kyoto, Japan
| | - Atsuko Murashima
- National Center for Child Health and Development, The Japan Drug Information Institute in Pregnancy, Tokyo, Japan
| | - Shinji Kosugi
- Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Kyoto, Japan
| |
Collapse
|
96
|
Abstract
An efficient method for the synthesis of 2,6-multisubstituted morpholines via an electrochemical intramolecular etherification has been developed. The method, which is operationally simple and easy to scale up, provides various substituted morpholine derivatives in high yields. The utility of this method is showcased by the synthesis of 2,2,6,6-tetrasubstituted morpholines, which are difficult to synthesize efficiently using previously reported strategies.
Collapse
Affiliation(s)
- Ryosuke Yamada
- Research Unit/Immunology & Inflammation, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan
| | - Komei Sakata
- Research Unit/Immunology & Inflammation, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan
| | - Takahiro Yamada
- Research Unit/Neuroscience, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 1000 Kamoshida-cho, Aoba-ku, Yokohama 227-0033, Japan
| |
Collapse
|
97
|
Miyata T, Mizushima T, Miyamoto N, Yamada T, Hase K, Fukushima M, Nishimura N, Hino S, Morita T. Skate-skin mucin, rich in sulfated sugars and threonine, promotes proliferation of Akkermansia muciniphila in feeding tests in rats and in vitro fermentation using human feces. Biosci Biotechnol Biochem 2022; 86:397-406. [PMID: 35026010 DOI: 10.1093/bbb/zbac003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 12/30/2021] [Indexed: 11/14/2022]
Abstract
Dietary factors, affect Akkermansia muciniphila (AM) abundance in the colon, have attracted attention, driven by the inverse correlation between AM abundance and metabolic disorders. We prepared skate-skin mucin (SM), porcine stomach mucin (PM), and rat gastrointestinal mucin (RM). SM contained more sulfated sugars and threonine than PM or RM. Rats were fed a control diet or diets including SM, PM, or RM (15 g/kg), or SM (12 g/kg) from 5 different threonine contents for 14 d. Cecal total bacteria and AM were less and more numerous, respectively, in SM-fed rats than the others, but SM did not affect microbial species richness. Low-threonine SM did not induce AM proliferation. The in vitro fermentation with human feces showed that the rate of AM increase was greater with SM than PM. Collectively, heavy SM sulfation facilitates a priority supply of SM-derived amino sugars and threonine that promotes AM proliferation in rats and human feces.
Collapse
Affiliation(s)
- Takaaki Miyata
- Department of Bioscience, Graduate School of Science and Technology, Shizuoka University, Shizuoka, Japan
| | - Takayasu Mizushima
- Department of Agriculture, Graduate School of Integrated Science and Technology, Shizuoka University, Shizuoka, Japan
| | | | - Takahiro Yamada
- Divisions of Biochemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan
| | - Koji Hase
- Divisions of Biochemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan
| | - Michihiro Fukushima
- Department of Life and Food Science, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Hokkaido, Japan
| | - Naomichi Nishimura
- College of Agriculture, Academic Institute, Shizuoka University, Shizuoka, Japan
| | - Shingo Hino
- College of Agriculture, Academic Institute, Shizuoka University, Shizuoka, Japan
| | - Tatsuya Morita
- College of Agriculture, Academic Institute, Shizuoka University, Shizuoka, Japan
| |
Collapse
|
98
|
Mizuta T, Kobayashi T, Yamakawa Y, Hanaoka K, Watanabe S, Morimoto-Ishikawa D, Yamada T, Kaida H, Ishii K. Initial evaluation of a new maximum-likelihood attenuation correction factor-based attenuation correction for time-of-flight brain PET. Ann Nucl Med 2022; 36:420-426. [PMID: 35138565 DOI: 10.1007/s12149-022-01721-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 01/17/2022] [Indexed: 11/01/2022]
Abstract
AIM The aim of this study was to evaluate an image reconstruction algorithm, including a new maximum-likelihood attenuation correction factor (ML-ACF) for time of flight (TOF) brain positron emission tomography (PET). METHODS The implemented algorithm combines an ML-ACF method that simultaneously estimates both the emission image and attenuation sinogram from TOF emission data, and a scaling method based on anatomical features. To evaluate the algorithm's quantitative accuracy, three-dimensional brain phantom images were acquired and soft-tissue attenuation coefficients and emission values were analyzed. RESULTS The heterogeneous distributions of attenuation coefficients in soft tissue, skull, and nasal cavity were sufficiently visualized. The attenuation coefficient of soft tissue remained within 5% of theoretical value. Attenuation-corrected emission showed no lateral differences, and significant differences among soft tissue were within the error range. CONCLUSION The ML-ACF-based attenuation correction implemented for TOF brain PET worked well and obtained practical levels of accuracy.
Collapse
Affiliation(s)
- Tetsuro Mizuta
- Medical Systems Division, Shimadzu Corporation, 1, Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto, 604-8511, Japan.
| | | | - Yoshiyuki Yamakawa
- Medical Systems Division, Shimadzu Corporation, 1, Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto, 604-8511, Japan
| | - Kohei Hanaoka
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan
| | - Shota Watanabe
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan
| | - Daisuke Morimoto-Ishikawa
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan
| | - Takahiro Yamada
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan
| | - Hayato Kaida
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan.,Department of Radiology, Kindai University Faculty of Medicine, Osakasayama, Japan
| | - Kazunari Ishii
- Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University, Osakasayama, Japan.,Department of Radiology, Kindai University Faculty of Medicine, Osakasayama, Japan
| |
Collapse
|
99
|
Tanaka S, Uchino J, Yokoi T, Kijima T, Goto Y, Suga Y, Katayama Y, Nakamura R, Morimoto K, Nakao A, Hibino M, Tani N, Takeda T, Yamaguchi H, Tachibana Y, Takumi C, Hiraoka N, Takeshita M, Onoi K, Chihara Y, Taniguchi R, Yamada T, Matsui Y, Hiranuma O, Morimoto Y, Iwasaku M, Tokuda S, Kaneko Y, Yamada T, Takayama K. Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer. Diagnostics (Basel) 2022; 12:diagnostics12020423. [PMID: 35204513 PMCID: PMC8870759 DOI: 10.3390/diagnostics12020423] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Revised: 01/31/2022] [Accepted: 02/04/2022] [Indexed: 12/04/2022] Open
Abstract
Combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapies (chemoimmunotherapy) is associated with significantly better survival outcomes than cytotoxic chemotherapies alone in patients with advanced non-small cell lung cancer (NSCLC). However, there are no prognostic markers for chemoimmunotherapy. The prognostic nutritional index (PNI) and lung immune prognostic index (LIPI) are prognostic biomarkers for immune checkpoint inhibitor (ICI) monotherapy or cytotoxic chemotherapies. Thus, we aimed to examine whether these factors could also be prognostic markers for chemoimmunotherapy. We retrospectively examined 237 patients with advanced NSCLC treated with chemoimmunotherapy. In the total group, the median overall survival (OS) was not reached, and the median progression-free survival (PFS) was 8.6 months. Multivariate analysis of OS and PFS revealed significant differences based on PNI and LIPI. Programmed cell death ligand 1 (PD-L1) was also significantly associated with OS and PFS. PNI and a PD-L1 tumor proportion score (TPS) of <50% and poor LIPI (regardless of PD-L1 TPS) were associated with poor prognosis. PNI and LIPI predicted survival outcomes in patients with advanced NSCLC treated with chemoimmunotherapy, especially in patients with PD-L1 TPS <50%. For patients in this poor category, chemoimmunotherapy may result in a worse prognosis than expected.
Collapse
Affiliation(s)
- Satomi Tanaka
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Junji Uchino
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
- Correspondence: ; Tel.: +81-75-251-5111
| | - Takashi Yokoi
- Department of Respiratory Medicine and Hematology and Department of Thoracic Oncology, Hyogo College of Medicine, 1-1 Mukogawachō, Nishinomiya 663-8501, Japan; (T.Y.); (T.K.)
| | - Takashi Kijima
- Department of Respiratory Medicine and Hematology and Department of Thoracic Oncology, Hyogo College of Medicine, 1-1 Mukogawachō, Nishinomiya 663-8501, Japan; (T.Y.); (T.K.)
| | - Yasuhiro Goto
- Department of Respiratory Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Japan;
| | - Yoshifumi Suga
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Yuki Katayama
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Ryota Nakamura
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Kenji Morimoto
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Akira Nakao
- Department of Respiratory Medicine, Faculty of Medicine, Fukuoka University, 8 Chome-19-1 Nanakuma, Jonan Ward, Fukuoka 814-0180, Japan;
| | - Makoto Hibino
- Department of Respiratory Medicine, Shonan Fujisawa Tokushukai Hospital, 1 Chome-5-1 Tsujidokandai, Fujisawa 251-0041, Japan;
| | - Nozomi Tani
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, 355-5, Haruobicho, Kamaza Dori Marutamachi Agaru, Kamigyo Ward, Kyoto 602-8026, Japan; (N.T.); (T.T.)
| | - Takayuki Takeda
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, 355-5, Haruobicho, Kamaza Dori Marutamachi Agaru, Kamigyo Ward, Kyoto 602-8026, Japan; (N.T.); (T.T.)
| | - Hiroyuki Yamaguchi
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan;
| | - Yusuke Tachibana
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, 15-749 Higashiyama Ward, Honmachi, Kyoto 605-0981, Japan; (Y.T.); (C.T.); (N.H.)
| | - Chieko Takumi
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, 15-749 Higashiyama Ward, Honmachi, Kyoto 605-0981, Japan; (Y.T.); (C.T.); (N.H.)
| | - Noriya Hiraoka
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, 15-749 Higashiyama Ward, Honmachi, Kyoto 605-0981, Japan; (Y.T.); (C.T.); (N.H.)
| | - Masafumi Takeshita
- Department of Respiratory Medicine, Ichinomiya Nishi Hospital, Hira-1 Kaimei, Ichinomiya City 494-0001, Japan;
| | - Keisuke Onoi
- Uji-Tokushukai Medical Center, Department of Respiratory Medicine, 145 Ishibashi Makishimacho, Uji-shi 611-0041, Japan; (K.O.); (Y.C.)
| | - Yusuke Chihara
- Uji-Tokushukai Medical Center, Department of Respiratory Medicine, 145 Ishibashi Makishimacho, Uji-shi 611-0041, Japan; (K.O.); (Y.C.)
| | - Ryusuke Taniguchi
- Department of Pulmonary Medicine, Matsushita Memorial Hospital, 5-55 Sotojima-cho, Moriguchi 570-8540, Japan; (R.T.); (T.Y.)
| | - Takahiro Yamada
- Department of Pulmonary Medicine, Matsushita Memorial Hospital, 5-55 Sotojima-cho, Moriguchi 570-8540, Japan; (R.T.); (T.Y.)
| | - Yohei Matsui
- Department of Pulmonary Medicine, Otsu City Hospital, 2-9-9 Motomiya, Otsu-City 520-0804, Japan; (Y.M.); (O.H.)
| | - Osamu Hiranuma
- Department of Pulmonary Medicine, Otsu City Hospital, 2-9-9 Motomiya, Otsu-City 520-0804, Japan; (Y.M.); (O.H.)
| | - Yoshie Morimoto
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Masahiro Iwasaku
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Shinsaku Tokuda
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Yoshiko Kaneko
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Tadaaki Yamada
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| | - Koichi Takayama
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan; (S.T.); (Y.S.); (Y.K.); (R.N.); (K.M.); (Y.M.); (M.I.); (S.T.); (Y.K.); (T.Y.); (K.T.)
| |
Collapse
|
100
|
Kondo T, Yamaguchi D, Matsubara J, Ura T, Nomura M, Funakoshi T, Yokoyama A, Doi K, Tamaoki M, Kou T, Itani T, Yoshimura M, Uza N, Yamada T, Masui T, Minamiguchi S, Ishikawa H, Matsumoto S, Muto M, Kanai M. Pathogenic variants of homologous recombination repair-related genes in advanced pancreatic cancer and oxaliplatin-based chemotherapy: Prospective multicenter observational study. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.4_suppl.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
555 Background: The latest National Comprehensive Cancer Network Guidelines for pancreatic adenocarcinoma recommended platinum-based chemotherapy for the patients with germline BRCA1/2 or PALB2 variants based on retrospective studies. However, the association between the efficacy of oxaliplatin-based chemotherapy and homologous recombination repair (HRR)-related gene variants has not yet been evaluated in a prospective study. Methods: This was a multicenter, prospective, observational study. Key inclusion criteria were: histologically confirmed pancreatic adenocarcinoma or adenosquamous carcinoma; candidates for systemic chemotherapy or currently under systemic chemotherapy for unresectable disease; age ≥ 20 years; Eastern Cooperative Oncology Group Performance Status 0–2; formalin-fixed paraffin-embedded cancer tissue available for genomic sequencing; and adequate hematological, liver, and renal function. Patients were assessed with the next generation sequencing (NGS)-based ACT-repair panel (ACT genomics; Taipei, Taiwan). ACT-repair panel is accredited by College of American Pathologists and is designed to detect short variants (SVs) including substitutions, insertions, deletions, and copy number variants of 35 genes including 8 HRR-related genes ( ATM, ATR, BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D). The primary endpoint was the one-year overall survival rate (1yr-OS%) after the initiation of oxaliplatin-based chemotherapy in patients who harbored pathogenic HRR gene variants. On the basis of published retrospective data, expected 1yr-OS% was set at ≥ 60% in this study. Results: Forty patients were enrolled from August 2018 to March 2020. Median age was 67 years (range, 49–81 years). Sequencing data were obtained from 39 patients (NGS success rate = 97.5%). Nine patients (22.5%) harboring HRR gene; ATM SVs (n = 4), BRCA2 loss of heterozygosity (LOH) (n = 3), BRCA2 SVs (n = 1), and PALB2 LOH (n = 1). Three patients received oxaliplatin-based chemotherapy as first-line chemotherapy, while the remaining six patients received it as second- or later-line oxaliplatin-based chemotherapy. The 1yr-OS% was 44.4%, and the median overall survival was 221 days (95% confidence interval, 79–NA days) after the initiation of oxaliplatin-based chemotherapy. In three patients who received oxaliplatin-based chemotherapy as first-line treatment, overall survivals were 703 (alive), 694 (alive), and 405 (dead) days, respectively. Conclusions: Efficacy of oxaliplatin-based chemotherapy on advanced pancreatic cancer harboring HRR-related gene variants did not meet the primary endpoint of 1yr-OS% (≥ 60%). Clinical trial information: UMIN000033655.
Collapse
Affiliation(s)
- Tomohiro Kondo
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Daisuke Yamaguchi
- Department of Medical Oncology, Kyoto-Katsura Hospital, Kyoto, Japan
| | - Junichi Matsubara
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Takashi Ura
- Department of Clinical Oncology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
| | - Motoo Nomura
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Taro Funakoshi
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Akira Yokoyama
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Keitaro Doi
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Masashi Tamaoki
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Tadayuki Kou
- Digestive Disease Center, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan
| | - Toshinao Itani
- Department of Gastroenterology, Kobe City Nishi-Kobe Medical Center, Hyogo, Japan
| | - Michio Yoshimura
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Norimitsu Uza
- Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Takahiro Yamada
- Department of Medical Ethics and Medical Genetics, Kyoto University School of Public Health, Kyoto, Japan
| | - Toshihiko Masui
- Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | | | - Hideki Ishikawa
- Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Shigemi Matsumoto
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Manabu Muto
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| | - Masashi Kanai
- Department of Clinical Oncology, Kyoto University Hospital, Kyoto, Japan
| |
Collapse
|